[go: up one dir, main page]

WO2024062208A1 - Compositions et méthodes de réduction du sulfure endogène chez des patients atteints de maladies inflammatoires de l'intestin - Google Patents

Compositions et méthodes de réduction du sulfure endogène chez des patients atteints de maladies inflammatoires de l'intestin Download PDF

Info

Publication number
WO2024062208A1
WO2024062208A1 PCT/GB2023/000044 GB2023000044W WO2024062208A1 WO 2024062208 A1 WO2024062208 A1 WO 2024062208A1 GB 2023000044 W GB2023000044 W GB 2023000044W WO 2024062208 A1 WO2024062208 A1 WO 2024062208A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
sulphide
colon
billion
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2023/000044
Other languages
English (en)
Inventor
Reuben Zachary WHEELER
Wanniarachchige Isiri Adhiwarie PERERA
Mian Chee GOR
Maria Rosita Icban CHUA
Remy Blair YOUNG
Lisa Michelle KIRKLAND
Samuel Paul COSTELLO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cost Bry Pty Ltd Trading Biomebank AS
Original Assignee
Cost Bry Pty Ltd Trading Biomebank AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2022902716A external-priority patent/AU2022902716A0/en
Application filed by Cost Bry Pty Ltd Trading Biomebank AS filed Critical Cost Bry Pty Ltd Trading Biomebank AS
Priority to JP2025511325A priority Critical patent/JP2025531029A/ja
Priority to CN202380067361.5A priority patent/CN120435301A/zh
Priority to CA3264675A priority patent/CA3264675A1/fr
Priority to IL319782A priority patent/IL319782A/en
Priority to AU2023345834A priority patent/AU2023345834A1/en
Priority to EP23783935.2A priority patent/EP4577226A1/fr
Publication of WO2024062208A1 publication Critical patent/WO2024062208A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Definitions

  • the present invention relates to compositions for treating inflammatory bowel disease.
  • the present invention also relates to dosage forms and methods of treating inflammatory bowel disease by administering the composition to a patient in need thereof.
  • the human intestinal microbiota consists of trillions of microorganisms, including at least 100 prevalent, and at least 1000 less common microbial species, harbouring over 100-fold more genes than those present in the human genome.
  • the intestinal microbiota is composed predominantly of bacteria, yet also contains archaea, protozoa, fungi and viruses.
  • the microbiota performs vital functions essential to health maintenance, including food processing, digestion of complex indigestible polysaccharides and synthesis of vitamins, and it secretes bioactive metabolites with diverse functions, ranging from inhibition of pathogens, metabolism of toxic compounds to modulation of host metabolism.
  • IBD Inflammatory bowel disease
  • UC ulcerative colitis
  • CD Crohn’s disease
  • pouchitis ulcerative colitis
  • UC ulcerative colitis
  • CD Crohn’s disease
  • UC chronic nongranulomatous inflammation that is limited to the colonic mucosa, typically involving the rectum and a variable proximal extent of the colon in continuity
  • CD is characterised by transmural, often granulomatous, inflammation that can involve any part of the gastrointestinal tract from the mouth to the anus.
  • the clinical presentation of UC is characterised by bloody diarrhoea with associated urgency, tenesmus, and lower abdominal pain. CD most frequently involves the terminal ileum and perianal regions, and structuring and fistulising disease are common. The clinical presentation of CD varies widely according to disease distribution, but is typically one of abdominal pain, diarrhoea, and weight loss. Extra-intestinal manifestations (EIMs) of IBD affect up to 50% of patients, typically in parallel with disease activity, and are more common in CD than in UC.
  • EIMs Extra-intestinal manifestations
  • EIM EIM’s of IBD
  • IBD The range of EIM’s of IBD is broad, including arthropathy, venous thromboembolic disease, metabolic bone disease, uveitis and scleritis, and skin disease (pyoderma granulosum, erythema nodosum).
  • Primary sclerosing cholangitis (PSC) is a hepatobiliary manifestation of IBD, affecting up to 5% of patients with IBD, which carries a high risk of progression to cholangiocarcinoma and liver transplantation.
  • IBD patients are also at increased risk of intestinal dysplasia and malignancy, in particular, those with extensive colitis for whom colonoscopic surveillance is recommended.
  • IBD The etiology of IBD is complex, multifactorial, and incompletely understood. Factors thought to play a role in the pathogenesis of IBD are host genetics, immune dysregulation, abnormal composition and function of the microbiome, and environmental factors.
  • UC ulcerative colitis .
  • Current treatments are hampered by incomplete efficacy and have the potential for unacceptable side-effects including allergy, intolerance, serious infection and malignancy due to long-term immunosuppression.
  • the current immune targeted therapies for UC are inadequate because they do not address the primary drivers of the disease, only the secondary immune response.
  • UC results from an energy deficiency state in colonocytes (colonic epithelial cells) induced by high levels of sulphide and nitric oxide (NO) depleting Coenzyme A (CoA) and inhibiting 0-oxidation of butyrate. Without energy in the form of adenosine triphosphate (ATP), colonocytes are unable to maintain the normal mucosal barrier that separates the luminal contents of the colon from the mucosal immune system. The loss of the mucus and tight junction barrier then allows activation of the mucosa immune system in a natural killer T-cell driven IL-13- and IL-5-dependent, TH2-mediated, immune response.
  • NO sulphide and nitric oxide
  • CoA Coenzyme A
  • ATP adenosine triphosphate
  • the process is as follows: (1 ) high levels of NO are damaging to human tissue; (2) the source of colonic NO is from anaerobic bacterial respiration or activated immune cells; (3) nitrosation of CoA then produces S-nitroso CoA (inactive) and (a) prevents the acetylation required for lipogenesis and (b) diminishes 0-oxidation of butyrate in colonocytes; (4) colonocyte energy deficiency follows with the inability to synthesis mucus, lipids and proteins;
  • Butyrate is the primary energy source of colonocytes
  • colonocytes rely exclusively on bacterial metabolic products for their energy. This is principally in the form of butyrate, a short chain fatty acid that is produced by the fermentation of dietary fibre in the right colon by members of the colonic microbiota.
  • Impairment of butyrate oxidation in colonocytes of UC patients is observed by measuring overall oxygen consumption and the contribution made to oxygen consumption by butyrate and glucose in quiescent, active and severe colitis.
  • SRB sulphate-reducing bacteria
  • SO X sulphur oxides
  • the gastrointestinal tract contains a potent immune system that is separated from the luminal microorganisms by barriers of the mucous layer and epithelium.
  • the innate immune system provides a further non-specific defense against invading organisms and is aided by the specific response to antigens provided by adaptive immune cells.
  • Current evidence from human studies indicates the mucosal inflammatory infiltrate in UC consists of a complex mixture of innate and adaptive immune cells and their products.
  • the management of UC involves both induction therapy (to induce remission) and maintenance therapy (to prevent further flares).
  • the goal of treatment is maintenance of remission without steroids.
  • Induction therapy is usually high dose oral 5-aminosalicylic acid compounds (5-ASAs) with or without topical 5-ASAs via enema or suppository. More severe flares require systemic corticosteroids (tapered over time and discontinued). Maintenance therapy choice in ulcerative colitis is determined by disease extent, severity, frequency of flares and past treatment history.
  • the mainstays of maintenance therapy are the 5-ASAs used orally or topically.
  • thiopurines should be used.
  • new biological agents have demonstrated efficacy for the maintenance of remission in UC. These are the anti-TNFa agents, infliximab, adalimumab and golimumab and the anti- integrin agent, vedolizumab. However, these agents are expensive and have incomplete efficacy.
  • the invention broadly resides in a composition for preventing or treating a gastrointestinal disorder in a subject in need thereof, said composition comprising at least one strain of a microorganism, wherein the microorganism is selected from the group consisting of: bacteria, archaea and yeast.
  • the microorganism comprises a phenotype and/or genes that are responsible for a phenotype selected from the group consisting of: reducing endogenous sulphide levels in the colon of a patient in need thereof; sulphide consumption; reducing sulphide and nitric oxide load on epithelial cells which affects cell respiration leading to a metabolic lesion; reducing relative abundance and or metabolic activity of sulphidogenic microbiota; reducing sulphide levels in the colon directly through consumption/assimilation/degradation; reducing sulphide levels, relative abundance and or metabolic activity of sulphidogenic microbiota in the colon by metabolic substrate competition; reducing sulphide levels, relative abundance and or metabolic activity of sulphidogenic microbiota in the colon by diverting metabolic substrates away from the production of sulphide; reducing sulphide levels, relative abundance and or metabolic activity of sulphidogenic microbiota in the colon by consuming
  • the microorganism comprises a phenotype and/or genes that are responsible for reducing endogenous sulphide levels in the colon of a patient in need thereof.
  • the microorganism comprises a phenotype and/or genes that are responsible for sulphide consumption.
  • the microorganism comprises a phenotype and/or genes that are responsible for reducing sulphide and nitric oxide load on epithelial cells which affects cell respiration leading to a metabolic lesion.
  • the microorganism comprises a phenotype and/or genes that are responsible for reducing the taxonomic diversity, number of species, relative abundance and or metabolic activity of sulphidogenic microbiota.
  • the microorganism comprises a phenotype and/or genes that are responsible for reducing sulphide levels in the colon directly through consumption/assimilation/degradation.
  • the microorganism comprises a phenotype and/or genes that are responsible for reducing sulphide levels, taxonomic diversity, number of species, relative abundance and or metabolic activity of sulphidogenic microbiota in the colon by metabolic substrate competition.
  • the microorganism comprises a phenotype and/or genes that are responsible for reducing sulphide levels, taxonomic diversity, number of species, relative abundance and or metabolic activity of sulphidogenic microbiota in the colon by diverting metabolic substrates away from the production of sulphide.
  • the microorganism comprises a phenotype and/or genes that are responsible for reducing sulphide levels, taxonomic diversity, number of species, relative abundance and or metabolic activity of sulphidogenic microbiota in the colon by consuming H2.
  • the microorganism comprises a phenotype and/or genes that are responsible for reducing sulphide levels, taxonomic diversity, number of species, relative abundance and or metabolic activity of sulphidogenic microbiota by reducing release of metabolizable sulphur substrates.
  • the microorganism comprises a phenotype and/or genes that are responsible for reducing sulphide levels, taxonomic diversity, number of species, relative abundance and or metabolic activity of sulphidogenic microbiota by reducing sulphur amino acid release (methionine, cysteine, homocysteine and/or taurine) into the colon.
  • the microorganism comprises a phenotype and/or genes that are responsible for reducing colonic protein fermentation; reducing nitric oxide production in the colon; and reducing nitric oxide levels in the colon.
  • the microorganism comprises a phenotype or genes that are responsible for the phenotype of sulphide consumption.
  • the sulphide is present in a form of sulphide selected from the group consisting of: a sulphide ion (S 2 ); a hydrosulphide (HSj ion; a bisulphide ion (SH ), hydrogen sulphide (H2S); an organic compound containing the group R- SH (a thiol); sulphide metals (including but not limited to iron, copper, and molybdenum sulphides.
  • the microorganism comprises a gene or several of the genes selected from the group consisting of: genes responsible for the use of sulphide in the biosynthesis of methionine and cysteine. [0051] In a further embodiment, the microorganism comprises a gene or several of the genes selected from the group consisting of: genes responsible for the anaerobic oxidation of sulphide.
  • the microorganism comprises a gene or several of the genes selected from the group consisting of: genes responsible for sulphide utilisation in the pathway of anaerobic ethanolamine utilisation.
  • the microorganism comprises a gene or several of the genes selected from the group consisting of: genes coding enzymes 2.3.1 .30, 2.5.1 .47, and/or 2.5.1 .65 of Figure 4; genes responsible for pathways listed in Table 6 regarding sulphur and sulphide metabolism and handling in the colon; and genes responsible for pathways listed in Table 7 regarding homo-acetogenesis and hydrogen cycling within the colon.
  • the microorganism is a species selected from the groups consisting of: a species selected from the group listed in Figure 5 and any combination thereof of these species.
  • the microorganism is selected from a phyla, selected from a genus, a species or an isolate selected from the groups consisting of: a species selected from the group listed in Figure 5 and any combination thereof of these species; an isolate selected from the group listed in Table 1 and any combination thereof of these isolates; a phyla selected from the group listed in Table 2 and any combination thereof of these phylum; a genus selected from the group listed in Table 3 and any combination thereof of these genera; a species selected from the group listed in Table 4 and any combination thereof of these species; an isolate selected from the group listed in Table 5 and any combination thereof of these isolates; an isolate selected from the group listed in Table 8 and any combination thereof of these isolates; and an isolate selected from the group listed in Table 9 and any combination thereof of these isolates.
  • the microorganism comprises a 16S ribosomal RNA (rRNA) gene or contiguous whole genome sequence having a nucleotide sequence selected from the group consisting of: SEQ ID NOs 1 to 9193.
  • rRNA ribosomal RNA
  • the microorganism comprises a 16S ribosomal RNA (rRNA) gene having a nucleotide sequence selected from the group consisting of: SEQ ID NOs 1 to 206.
  • rRNA ribosomal RNA
  • the microorganism comprises whole genome sequences having a nucleotide sequence selected from the group consisting of: SEQ ID NOs 207 to 412. [0059] In a further preferred embodiment, the microorganism comprises whole genome sequences having a nucleotide sequence selected from the group consisting of: SEQ ID NOs 413-9193.
  • the microorganism comprises a 16S ribosomal RNA (rRNA) gene or contigous whole genome sequence having a sequence identity to one or more SEQ ID NOs 1 to 9193, wherein the sequence identity is selected from the group consisting of: at least 99.9%; at least 99.5%; at least 99%; at least 98.5%; at least 98%; at least 97.5%; at least 97%; at least 96.5%; at least 96%; at least 95.5%; at least 95%; at least 94.5%; at least 94%; at least 93.5%; at least 93%; at least 92.5%; at least 92%; at least 9 .5%; at least 91 %; at least 90.5% and at least 90%.
  • rRNA 16S ribosomal RNA
  • the microorganism is a faecal or colonic microorganism.
  • the microorganism is non-inflammatory.
  • the microorganism is cultured from a faecal or colonic biopsy sample.
  • the microorganism comprises a community of microorganism cells derived from a stool or biopsy of one or more human donors.
  • the community of microorganism cells comprises cultured microorganism cells.
  • the cultured microorganism cells are derived from a multiple of human donors.
  • the community of microorganism cells comprises uncultured microorganism cells.
  • the uncultured microorganism cells are derived from a single human donor.
  • the composition is a faecal transplant microbiota composition.
  • the composition is lyophilized.
  • the composition is a liquid. [0072] In a further preferred embodiment, after at least 4 weeks of storage at room temperature, said composition is capable of maintaining at least 50% cell viability relative to the initial cell viability immediately prior to storage.
  • said composition is capable of maintaining about 60% to about 80% cell viability relative to the initial cell viability immediately prior to the start of said storage.
  • the composition comprises a prebiotic.
  • the composition comprises a carrier.
  • the composition comprises an insoluble fibre, a buffer, an antioxidant, an osmotic agent, an antifoaming agent, and/or a preservative.
  • the composition comprises a chemostat medium.
  • the composition comprises a saline composition.
  • the composition comprises a resistant starch.
  • composition is lyophilized with pharmaceutically acceptable excipients.
  • the composition comprises a stabiliser and/or cryoprotectant.
  • the cryoprotectant is selected from the group consisting of: trehalose; mannitol; sucrose; glycerol; sorbitol; DMSO; propylene glycol; ethylene glycol; saccharose; galactose-lactose; inulin; maltodextrin; glutathione; and any combination thereof.
  • the said cryoprotectant further comprises a compound selected from the group consisting of: glycerol; polyethylene glycol (PEG); glycerin; erythritol; arabitol; xylitol; sorbitol; glucose; lactose; ribose; and any combination thereof.
  • glycerol polyethylene glycol (PEG); glycerin; erythritol; arabitol; xylitol; sorbitol; glucose; lactose; ribose; and any combination thereof.
  • the said cryoprotectant is trehalose at a concentration of 2% to 15% in said lyophilized formulation.
  • the said cryoprotectant is trehalose at a concentration of at least 5% in said lyophilized formulation. [0086] In a further preferred embodiment, the said cryoprotectant is trehalose at a concentration of at least 10% in said lyophilized formulation.
  • the said composition is a pharmaceutical composition.
  • At least one strain of microorganism is diluted with an inert powdered diluent.
  • the said composition comprises one or more pharmaceutically acceptable carriers or excipients.
  • the said composition is formulated as a geltab, pill, enema, microcapsule, capsule, or tablet.
  • the capsule or tablet is enteric-coated, pH- dependent, slow-release, and/or gastro-resistant.
  • composition is adapted for administration orally or rectatly.
  • every 200 mg of the composition comprises a pharmacologically active dose of microorganism cells or spores selected from the group consisting of: 10 1 to 10 14 ; 10 1 to 10 16 ; 10 2 to 10 14; 10 3 to 10 14 ; 10 4 to 10 14 ; 10 5 to 10 14 ;10 6 to 10 14 ; 10 7 to 10 14 ; 10® to 10 14 ; 10 4 to 10 13 ; 10® to 10 12 ; 10® to 10 11 ; 10 7 to 10 1 °; 10® to 10 9 ; 10 3 to 10 13 ; 10 3 to 10 12 ; 10 3 to 10 11 ; 10 3 to 10 1 °; 10 3 to 10 9 ; 10 3 to 10®; 10 3 to 10 7 ; 10 3 to 10 5 ; 10 3 to 10 5 , and 10 3 to 10 4 colony forming units (cfu) or total cell count.
  • a pharmacologically active dose of microorganism cells or spores selected from the group consisting of: 10 1 to 10 14 ;
  • the composition comprises a pharmacologically active dose of microorganism cells or spores selected from the group consisting of: from 1 cfu/mL to 10 cfu/mL, 100 cfu/mL to 1 thousand cfu/mL, 10 thousand cfu/mL to 100 thousand cfu/mL, from 10 cfu/mL to 10 6 cfu/mL, from 100 cfu/mL to 10 6 cfu/mL, from 1000 cfu/mL to 10 6 cfu/mL, from 10000 cfu/mL to to 10 6 cfu/mL, from 100000 cfu/mL to 10 6 cfu/mL, from 10 1 cfu/mL to 10 6 cfu/mL, 1 cfu/mL to 10 cfu/mL, 100 cfu/mL to 1 thousand c
  • the composition comprises a pharmacologically active dose of microorganism cells or spores wherein the concentration of the microorganism cells or spores as a dry microbial body, is selected from the group consisting of: between 5 to 50 w/w %, 1 to 75 w/w %, 0.1 to 100 w/w % and 1 to 100 w/w %.
  • the gastrointestinal disorder is gastrointestinal tract mucosal inflammation.
  • the gastrointestinal disorder is dysbiosis.
  • the inflammation is associated with one or more of disorders selected from the group consisting of: inflammatory bowel disease (IBD), pouchitis, irritable bowel syndrome (IBS), an enteric bacterial infection, a metabolic disease, a neuropsychiatric disorder, an autoimmune disease, an allergic disorder, hepatic encephalopathy, or a cancer.
  • IBD inflammatory bowel disease
  • IBS irritable bowel syndrome
  • enteric bacterial infection a metabolic disease
  • a neuropsychiatric disorder a neuropsychiatric disorder
  • an autoimmune disease an allergic disorder
  • hepatic encephalopathy or a cancer.
  • the gastrointestinal disorder is an inflammatory bowel disease.
  • the inflammatory bowel disease is selected from the group consisting of: ulcerative colitis; Crohn's disease; gastroenteritis; colitis; and pouchitis.
  • the gastrointestinal disorder is selected from the group consisting of: irritable bowel syndrome; an ulcer of the gastrointestinal tract; a cancer of the gastrointestinal tract.
  • the composition reduces endogenous sulphide levels in the colon of a patient in need thereof.
  • the composition reduces sulphide and NO load on epithelial cells leading to a metabolic lesion via inhibition of cellular respiration.
  • the composition reduces the taxonomic diversity, number of species, relative abundance, and/ or metabolic activity of sulphidogenic microbiota; reduces sulphide levels in the colon directly through consumption/assimilation/degradation; reduces sulphide levels in the colon via metabolic substrate competition; and or reduces sulphide levels in the colon by consuming hydrogen.
  • the composition reduces the taxonomic diversity, number of species, relative abundance and/ or metabolic activity of sulphidogenic microbiota by reducing metabolizable sulphur substrates; reduce sulphur amino acid release (methionine, cysteine, homocysteine, taurine) into the colon by reducing protein fermentation.
  • the composition reduces the taxonomic diversity, number of species, relative abundance, and/or metabolic activity of sulphidogenic microbiota.
  • the composition reduces sulphide levels in the colon directly through consumption/assimilation/degradation.
  • the composition reduces sulphide levels in the colon by consuming hydrogen.
  • the composition reduces the taxonomic diversity, number of species, relative abundance and/or metabolic activity of sulphidogenic microbiota by reducing metabolisable sulphur substrates.
  • the composition reduces sulphur amino acid release (methionine, cysteine, homocysteine, taurine) into the colon by reducing protein fermentation.
  • the composition reduces sulphide levels in the colon via metabolic substrate competition. In a further preferred embodiment, the composition drives down undesired inflammation.
  • the composition prevents or reduces activation of the mucosa immune system in a natural killer T-cell driven IL-13 and IL-5 dependent, TH2- mediated, immune response.
  • the composition decreases inflammation in the subject when measured by a parameter selected from the group consisting of: TNFa signalling via NF-KB; IFNa signalling; IFNy signalling; IL6 JAK STAT3 signalling; activation of pro- apoptotic pathways; initiation of unfolded protein response.
  • the composition down-regulates genes associated with pro-apoptotic pathways and the unfolded protein response, including genes selected from the group consisting of: CHAC1 , CEBPB, TRIB3, PPP1 R15A, DDIT3, ATF4 and XBP1.
  • the composition comprises at least one strain of a microorganism selected from the group consisting of: Flavinofractor spp.; Flavinofractor plautii; Christensenella spp.; Christensenella minuta; Anaerobutyricum spp.; Anaerobutyricum hallii; Escherichia-Shigella spp.; and Escherichia coli; or a combination of two or more strains thereof.
  • the composition is used for treating or preventing ulcerative colitis.
  • the composition is used for treating or preventing IBD.
  • the composition comprises at least one strain of a microorganism selected from the group consisting of: Flavinofractor spp.
  • the composition comprises at least one strain of a microorganism selected from the group consisting of: Flavinofractor plautii.
  • the composition comprises at least one strain of a microorganism selected from the group consisting of: Christensenella spp.
  • the composition comprises at least one strain of a microorganism selected from the group consisting of: Christensenella minuta.
  • the composition comprises at least one strain of a microorganism selected from the group consisting of: Anaerobutyricum spp.
  • the composition comprises at least one strain of a microorganism selected from the group consisting of: Anaerobutyricum hallii.
  • the composition comprises at least one strain of a microorganism selected from the group consisting of: Escherichia-Shigella spp.
  • the composition comprises at least one strain of a microorganism selected from the group consisting of: Escherichia coli.
  • the composition further comprises dietary fibre.
  • the dietary fibre is selected from the group consisting of: FOS, inulin, maltodextrin, and starch.
  • the invention broadly resides in a biotherapeutic composition comprising the composition of the first aspect of the invention, together with an acceptable diluent or carrier.
  • the composition further comprises dietary fibre.
  • the dietary fibre is selected from the group consisting of: FOS, inulin, maltodextrin, and starch.
  • the invention broadly resides in a pharmaceutical composition comprising the composition of the first aspect of the invention, together with a pharmaceutically acceptable diluent or carrier.
  • the composition further comprises dietary fibre.
  • the dietary fibre is selected from the group consisting of: FOS, inulin, maltodextrin, ard starch.
  • the invention broadly resides in an isolated non-inflammatory strain of microorganism comprising a 16S ribosomal RNA (rRNA) gene having a nucleotide sequence selected from the group consisting of: SEQ ID NOs 1 to 9193.
  • rRNA ribosomal RNA
  • the invention broadly resides in an isolated non-inflammatory strain of microorganism comprising a contiguous whole genome sequence having a nucleotide sequence selected from the group consisting of: SEQ ID NOs 1 to 9193.
  • the isolated non-inflammatory strain of microorganism comprises a 16S ribosomal RNA (rRNA) gene or conitgous whole genome sequence having a sequence identity to one or more SEQ ID NOs 1 to 9193, wherein the sequence identity is selec.ed from the group consisting of: at least 99.9%; at least 99%; at least 98%; at least 97%; a: least 96%; at least 95%; at least 94%; at least 93%; at least 92%; at least 91 %; and at least 90%.
  • rRNA 16S ribosomal RNA
  • the invention broadly resides in a method of treating and/or preventing a gastrointestinal disorder in a patient in need thereof said method comprising the step of administering the composition of the invention to a patient in need thereof.
  • the gastrointestinal disorder is gastrointestinal tract mucosal inflammation.
  • the gastrointestinal disorder is dysbiosis.
  • the inflammation is associated with one or more of the disorders selected from the group consisting of: inflammatory bowel disease (IBD), pouchitis, irritable bowel syndrome (IBS), an enteric bacterial infection, a metabolic disease, a neuropsychiatric disorder, an autoimmune disease, an allergic disorder, hepatic encephalopathy, or a cancer.
  • IBD inflammatory bowel disease
  • IBS irritable bowel syndrome
  • enteric bacterial infection a metabolic disease
  • a neuropsychiatric disorder a neuropsychiatric disorder
  • an autoimmune disease an allergic disorder
  • hepatic encephalopathy or a cancer.
  • the gastrointestinal disorder is an inflammatory bowel disease.
  • the inflammatory bowel disease is selected from the group consisting of: ulcerative colitis; Crohn's disease; gastroenteritis; colitis; and pouchitis.
  • the gastrointestinal disorder is selected from the group consisting of: irritable bowel syndrome; an ulcer of the gastrointestinal tract; a cancer of the gastrointestinal tract.
  • composition is administered orally or rectally.
  • the said composition is administered to the patient using a dosing regimen selected from the group consisting of: once-off; hourly; every 2 hours; every 3 hours; every 4 hours; every 5 hours; every 6 hours; every 12 hours; once daily; twice daily; every 2 days; every 3 days; every 4 days; every 5 days; every 6 days; weekly; twice weekly; every 2 weeks; every 3 weeks; every 4 weeks; every 5 weeks; every 6 weeks; once monthly; twice monthly; every 2 months; every 3 months; every 4 months; every 5 months; every 6 months; yearly; twice yearly; every 2 years; every 3 years; every 4 years; and every 5 years.
  • a dosing regimen selected from the group consisting of: once-off; hourly; every 2 hours; every 3 hours; every 4 hours; every 5 hours; every 6 hours; every 12 hours; once daily; twice daily; every 2 days; every 3 days; every 4 days; every 5 days; every 6 days; weekly; twice weekly; every 2 weeks; every 3 weeks; every 4 weeks; every 5 weeks; every 6 weeks; once
  • the composition reduces endogenous sulphide levels in the colon of a patient in need thereof.
  • the composition reduces sulphide and nitric oxide load on epithelial cells leading to a metabolic lesion via inhibition of cellular respiration.
  • the composition reduces nitric oxide production and/or reduces nitric oxide levels in the colon.
  • the composition reduces the taxonomic diversity, reduces the number of species, reduces the relative abundance and/ or reduces the metabolic activity of sulphidogenic microbiota; reduces sulphide levels in the colon directly through consumption/assimilation/degradation; reduces sulphide levels, taxonomic diversity, number of, relative abundance and or metabolic activity of sulphidogenic microbiota via metabolic substrate competition; and/or reduces sulphide levels, taxonomic diversity, number of, relative abundance and or metabolic activity of sulphidogenic microbiota by consuming hydrogen.
  • the composition reduces the taxonomic diversity, reduces the number of species, reduces the relative abundance and/or reduces the metabolic activity of sulphidogenic microbiota. [00143] In a further preferred embodiment, the composition reduces sulphide levels in the colon directly through consumption/assimilation/degradation. by consuming hydrogen.
  • composition the taxonomic diversity reduces the number of species, reduces the relative abundance and/or reduces the metabolic activity sulphidogenic microbiota via metabolic substrate competition.
  • the composition reduces sulphide levels, reduces the taxonomic diversity, reduces the number of species, reduces the relative abundance and/or reduces the metabolic activity of sulphidogenic microbiota by consuming hydrogen.
  • the composition reduces the taxonomic diversity, reduces the number of species, reduces the relative abundance and/or reduces the metabolic activity of sulphidogenic microbiota by reducing metabolizable sulphur substrates in the colon; and/or reduces the taxonomic diversity, number of species, relative abundance and/or metabolic activity of sulphidogenic microbiota by reducing sulphur amino acid release (methionine, cysteine, homocysteine, taurine) into the colon by reducing protein fermentation.
  • sulphur amino acid release methionine, cysteine, homocysteine, taurine
  • the composition reduces the rate or concentration of sulphide produced in the colon by increasing the taxonomic diversity, the number of species, relative abundance and/or metabolic activity of sulphide consuming/assimilating/degrading isolates.
  • the composition reduces the rate or concentration of sulphide produced in the colon by increasing the taxonomic diversity, number of species, relative abundance and/or metabolic activity of sulphide consuming/assimilating/degrading isolates relative to the number of species, the taxonomic diversity or relative abundance of sulphidogenic microbiota.
  • the method drives down undesired inflammation.
  • the composition comprises a strain selected from the group consisting of: Flavinofractor spp.; Flavinofractor plautii; Christensenella spp.; Christensenella minuta; Anaerobutyricum spp.; Anaerobutyricum hallii; Escherichia-Shigella spp.; and Escherichia coli.
  • the composition comprises at least one strain of a microorganism selected from the group consisting of: Flavinofractor spp. [00152] In a further preferred embodiment, the composition comprises at least one strain of a microorganism selected from the group consisting of: Flavinofractor plautii.
  • the composition comprises at least one strain of a microorganism selected from the group consisting of: Christensenella spp.
  • the composition comprises at least one strain of a microorganism selected from the group consisting of: Christensenella minuta.
  • the composition comprises at least one strain of a microorganism selected from the group consisting of: Anaerobutyricum spp.
  • the composition comprises at least one strain of a microorganism selected from the group consisting of: Anaerobutyricum hallii.
  • the composition comprises at least one strain of a microorganism selected from the group consisting of: Escherichia-Shigella spp.
  • the composition comprises at least one strain of a microorganism selected from the group consisting of: Escherichia coli.
  • the composition is administered with dietary fibre.
  • dietary fibre is selected from the group consisting of: FOS, inulin, maltodextrin, and starch.
  • the dietary fibre is administered concurrently or sequentially with the composition.
  • the composition prevents or reduces activation of the mucosa immune system in a natural killer T-cell driven IL-13 and IL-5 dependent, TH2 mediated, immune response.
  • the said method decreases inflammation in the subject when measured by a parameter selected from the group consisting of: TNFo signalling via NF-KB; IFNO signalling; IFNy signalling; IL6 JAK STAT3 signalling; activation of pro- apoptotic pathways; initiation of unfolded protein response.
  • the said method down regulates genes associated with pro-apoptotic pathways and the unfolded protein response, including genes selected from the group consisting of: CHAC1 , CEBPB, TRIB3, PPP1 R15A, DDIT3, ATF4 and XBP1.
  • the invention broadly resides in a method of reducing endogenous sulphide levels in the colon of a patient in need thereof.
  • the method reduces sulphide and nitric oxide load on epithelial cells leading to a metabolic lesion via inhibition of cellular respiration.
  • the method reduces relative abundance and or metabolic activity of sulphidogenic microbiota.
  • the method reduces sulphide levels in the colon directly through consumption/assimilation/degradation.
  • the method reduces sulphide levels, taxonomic diversity, number of species, relative abundance and/or metabolic activity of sulphidogenic microbiota in the colon by metabolic substrate competition.
  • the method reduces sulphide levels, taxonomic diversity, number of species, and relative abundance and/or metabolic activity of sulphidogenic microbiota ir the colon by consuming hydrogen.
  • the method reduces sulphide levels, taxonomic diversity, number of species, and relative abundance and/or metabolic activity of sulphidogenic microbiota by reducing metabolisable sulphur substrates in the colon.
  • the method reduces sulphide levels, the taxonomic diversity, numoer of species, relative abundance and/or metabolic activity of sulphidogenic microbiota by reducing sulphur amino acid release (methionine, cysteine, homocysteine, taurine) into the colon.
  • the method reduces sulphide levels, the taxonomic diversity, number of species, relative abundance and/or metabolic activity of sulphidogenic microbiota in the colon by reducing protein fermentation.
  • the invention broadly resides in a method of preparing the biotherapeutic composition according to the second aspect of the invention, the method comprising mixing the composition according to the first aspect of the invention with an acceptable diluent or carrier.
  • the invention broadly resides in a method of preparing the pharmaceutical composition according to the third aspect of the invention, the method comprising mixing the composition according to the first aspect of the invention with a pharmaceutically acceptable diluent or carrier.
  • the invention broadly resides in the use of the composition according to the first aspect of the invention in the manufacture of a medicament for reducing or preventing gastrointestinal disorder in a subject.
  • the invention broadly resides in a dosage form comprising the composition of the first aspect of the invention.
  • the invention broadly resides in a kit comprising the dosage form according to the tenth aspect of the invention together with instructions for its use.
  • the invention broadly resides in a nucleotide sequence selected from the group consisting of: SEQ ID NOs 1 to 9193.
  • the invention is a nucleotide sequence having a sequence identity to one or more SEQ ID NOs 1 to 9193, wherein the sequence identity is selected from the group consisting of: at least 99.9%; at least 99%; at least 98%; at least 97%; at least 96%; at least 95%; at least 94%; at least 93%; at least 92%; at least 91%; and at least 90%.
  • the nucleotide sequence is substantially purified or isolated.
  • the invention is a micro-organism comprising a nucleotide sequence selected from the group consisting of: SEQ ID NOs 1 to 9193.
  • the invention is a micro-organism comprising a nucleotide sequence having a sequence identity to one or more SEQ ID NOs 1 to 9193, wherein the sequence identity is selected from the group consisting of: at least 99.9%; at least 99%; at least 98%; at least 97%; at least 96%; at least 95%; at least 94%; at least 93%; at least 92%; at least 91 %; and at least 90%.
  • the micro-organism is substantially purified or isolated.
  • Figure 1 shows tie diagrammatical representation of the processes that lead to ulcerative colitis induced by high levels of sulphide (either as a sulphide ion (S 2- ), a bifsulphide ion (SHj, or hydrogen sulphide (H 2 S)) and nitric oxide (NO).
  • S 2- sulphide ion
  • SHj bifsulphide ion
  • NO nitric oxide
  • Figure 2 shows a graphical representation of hydrogen competition between methanogens, acetogens and sulphate-reducing bacteria. Competition for hydrogen by methanogens and acetogens leads to a decrease in the activity and abundance of sulphate- reducing bacteria, resulting in decreased production of sulphide.
  • Figure 3 shows the BB265 drug discovery process detailing lead selection and BB265 mechanistic validation prior to clinical validation in a phase 1 trial.
  • Figure 4 shows the cysteine biosynthesis pathway outlined in red, a pathway by which sulphide can be directly consumed by colonic microbiota. This pathway was obtained from https://www.Qenome.ip/pathwav/map00270.
  • Figure 5 shows a table of taxa of all 143 isolates comprising the BB265 complex consortium along with all isolates outside of the consortium identified with a sulphide consumption phenotype. Complete taxonomic lineages and taxon identifications are displayed for each isolate.
  • Figure 6 shows a table of the V3-V4 hypervariable region of the 16S rRNA gene sequences taken from the isolates listed in Figure 5. These sequences are SEQ ID No 1-206 (a total of 206 sequences). These sequences are used for taxonomic classification of microbial species because the 16S rRNA gene, which is a small ribosomal subunit, is conserved amongst microbial species, whilst containing hypervariable regions, such as the V3-V4 region, which provides sufficient variation to determine species-level discrimination between 16 rRNA gene sequences. The sequences presented are DNA sequences encoding the ribosomal RNA.
  • Figure 7 shows a table of the full-length 16S rRNA gene sequences taken from the isolates listed in Figure 5. These sequences are SEQ ID No 207-412 (a total of 206 sequences). These sequences are used for taxonomic classification of microbial species because the 16S rRNA gene, which is a small ribosomal subunit, is conserved amongst microbial species whilst containing hypervariable regions, such as the V3-V4 region, which provides sufficient variation to determine species-level discrimination between 16 rRNA gene sequences. The sequences presented are DNA sequences encocing the ribosomal RNA.
  • Figure 8 shows a table of contiguous DNA sequences derived from whole genomes of the isolates listed in Table 5. These sequences are SEQ ID No 413 - 9193 (a total of 8781 sequences. These sequences taken together comprise the whole-genome sequence of the specific isolates listed in Table5. The sequences presented are DNA sequences encoding the ribosomal RNA.
  • Figure 9 shows the amount of sulphide, expressed in mM, consumed by microbial isolates identified to have a statistically significant sulphide consumption phenotype relative to the negative control when assayed for sulphide consumption using the in-house modified methylene blue assay.
  • Figure 10 shows a flow chart of the tri-tool consensus analysis used to identify taxa that discriminate between health and ulcerative colitis from large faecal metagenome datasets.
  • Figure 11 shows a phylogenetic tree displaying the sulphide phenotype of the 12,607 isolates from the inventors’ culture collection assayed for sulphide production.
  • Tree construction was performed using FastTree v2.1 .11 to infer maximum likelihood trees with the generalised time-reversible (GTR) with CAT approximation model. The tree was visualised with R package ggtree v3.6.2 and R package ggtree Extra v1 .8.1 .
  • Figure 12a shows box and whisker plots representing the changes in the number of BB265 species in patients who achieved remission from FMT in a clinical trial.
  • Week 0 indicates the number of species prior to remission when patient disease state was considered active;
  • Week 12 is post FMT treatment during remission.
  • Figure 12b shows box and whisker plots representing the cumulative relative abundance of sulphide consumer species in patients who achieved remission from FMT in a clinical trial.
  • Week 0 indicates the number or abundance of species prior to remission when patient disease state was considered active;
  • Week 12 is post FMT Treatment during remission.
  • Figure 12c shows box and whisker plots representing the number of sulphide consumer species in patients who achieved remission from FMT in a clinical trial.
  • Week 0 indicates the number or abundance of species prior to remission when patient disease state was considered active;
  • Week 12 is post FMT treatment during remission.
  • Figure 13a shows box and whisker plots representing the average concentrations of aqueous sulphide (pM) in stool samples of Patient D post incubation in half strength YCFA with sodium sulphite and Solution I. Stool samples were collected during active disease and during remission following FMT.
  • pM aqueous sulphide
  • Figure 13b shows box and whisker plots representing the average concentrations of aqueous sulphide (pM) in stool samples of Patient E post incubation in half strength YCFA with sodium sulphite and Solution I. Stool samples were collected during active disease and during remission following FMT.
  • pM aqueous sulphide
  • Figure 13c shows bar graphs representing the number of BB265 species identified in stool samples from Patient D and E during active disease (Baseline) and remission following FMT.
  • Figure 13d shows bar graphs representing
  • Figure 13e shows bar graphs representing the cumulative abundance of sulphidogenic species identified in stool samples from Patients D and E during active disease (Baseline) and remission following FMT.
  • Figure 14 shows box and whisker plots representing the average reduction in aqueous sulphide concentration (pM) in two ulcerative colitis patient stool samples (Patient A and B) co-incubated with a subset of the BB265 complex consortium comprising 127 of the 143 isolates. Reduction in aqueous sulphide is displayed as concentration (pM) change from negative control, which consists of stool incubated in media only.
  • PDCM Phylogenetically diverse consumer mix refers to ulcerative colitis stool co-incubated with 19 isolates of BB265 phenotypically confirmed as sulphide consumers using the modified methylene blue assay.
  • Figure 16 shows box and whisker plots representing the average reduction in aqueous sulphide concentration in ulcerative colitis patient stool samples (Patient A and C) co-incubated with the BB265 complex consortium. Reduction in aqueous sulphide is displayed as change in concentration (pM) from the negative control, which consists of stool incubated in media only. Individual consumer refers to ulcerative colitis stool co-incubated with the individual strong sulphide consumer, bb0214 which displayed 670 pM H2S consumption using the modified methylene blue assay.
  • Figure 17 shows a phylogenetic tree displaying the sulphide consumer and corresponding sulphidogenic phenotypes of the 275 purified microbial isolates assayed for sulphide consumption using the in-house modified methylene blue assay. Colours on tree tips represent phyla and the inner ring bar graph represents the average concentration of sulphide consumed by isolates (pM). Isolate identifiers are present for those isolates in the BB265 complex consortium and for isolates identified dith net average sulphide consumption.
  • the inner-outer and outer-outer rings show sulphide production from cysteine and thiosulphate, respectively; ‘N’ refers to a negative phenotype whereas ‘Y’ refers to a positive phenotype.
  • Tree construction was performed using FastTree v2.1 .11 to infer maximum likelihood trees with the generalised time-reversible (GTR) with CAT approximation model. The tree was visualised with R package ggtree v3.6.2 and R package ggtreeExtra v1 .8.1 .
  • Figure 18 shows a line graph representing the accumulation of H 2 S overtime due to microbial production of hydrogen sulphide in an ulcerative colitis patient (Patient A) stool sample alone, healthy donor (Donor A) stool sample alone, and when the ulcerative colitis patient (Patient A) stool sample was co-incubated with the BB265 complex consortium, and a sulphide consumer ( bb0214). Healthy Donor A was used as a healthy comparison for hydrogen sulphide production. Concentration of H2S is displayed in pM.
  • Figure 19 shows a line graph representing the accumulation of H 2 S overtime due to microbial production of hydrogen sulphide in an ulcerative colitis patient (Patient C) stool sample alone, healthy donor (Donor C) stool sample alone, and when the ulcerative colitis patient (Patient A) stool sample was co-incubated with the BB265 complex consortium, and a sulphide consumer ( bb0450). Healthy Donor C was used as a healthy comparison for sulphide production. Concentration of H 2 S is displayed in pM.
  • Figure 20 shows a line graph representing the rate of H 2 S production due to microbial production of hydrogen sulphide in an ulcerative colitis patient (Patient A) stool sample alone, healthy donor (Donor A) stool sample alone, and when the ulcerative colitis patient (Patient A) stool sample was co-incubated with the BB265 complex consortium, and a sulphide consumer ( bb0214). Healthy Donor A was used as a healthy comparison for sulphide production. Rate of H 2 S production is displayed in pM hr 1
  • Figure 21 shows a line graph representing the rate of H 2 S production due to microbial production of hydrogen sulphide in an ulcerative colitis patient (Patient C) stool sample alone, healthy donor (Donor C) stool sample alone, and when the ulcerative colitis patient (Patient C) stool sample was co-incubated with the BB265 complex consortium, and a sulphide consumer (bb0450). Healthy Donor A was used as a healthy comparison for sulphide production. Rate of H 2 S production is displayed in pM hr 1
  • Figure 22 shows a dot plot representing the effect of fibre with and without with the 127-isolate subset of the BB265 complex consortium on the concentration of sulphide (pM) post fermentation of ulcerative colitis stool samples from Patients A , B and F.
  • Fibres tested were: FOS, Inulin, Maltodextrin and Starch.
  • Figure 23a shows a bar graph representing the effect of co-culturing ulcerative colitis stool (Patient A and Patient C)with the 127-isolate subset of the BB265 complex consortium on the number and cumulative relative abundances of putative sulphidogenic species achieved from Shotgun metagenomics in the stool samples of Patient A and B.
  • Figure 23b shows a bar graph representing the effect of co-culturing ulcerative colitis stool (Patient and Patient C) with the 127-isolate subset of the BB265 complex consortium on the number and cumulative relative abundances of sulphide consuming species achieved from Shotgun metagenomics in the stool samples of Patient A and B.
  • Figure 23c shows a bar graph representing the effect of co-culturing ulcerative colitis stool (Patient and Patient C) with the 127-isolate subset of the BB265 complex consortium on the number and accumulate relative abundances of species comprising the BB265 complex consortium achieved from Shotgun metagenomics in the stool samples of Patient A and B
  • Figure 24a shows a bar graph representing the number and abundance of BB265, phenotypically identified consumers and producers achieved from shotgun metagenomics in the stool sample of Patient A when inoculated with the strong consumer bb0214 and the 127- isolate subset of BBB265 post incubation.
  • Figure 24b shows a bar graph representing the cumulative relative abundance ofsulphidogens achieved from shotgun metagenomics in the stool sample of Patient A when inoculated with the strong consumer bb0214 and the 127-isolate subset of the BBB265 complex consortium post incubation.
  • the invention described herein may include one or more range of values (e.g. size, concentration etc.).
  • a range of values will be understood to include all values within the range, including the values defining the range, and values adjacent to the range which lead to the same or substantially the same outcome as the values immediately adjacent to that value which defines the boundary to the range.
  • a person skilled in the field will understand that a 10% variation in upper or lower limits of a range can be totally appropriate and is encompassed by the invention. More particularly, the variation in upper or lower limits of a range will be 5% or as is commonly recognised in the art, whichever is greater.
  • “Therapeutically effective amount” as used herein with respect to methods of treatment and in particular drug dosage shall mean that dosage that provides the specific pharmacological response for which the drug is administered in a significant number of subjects in need of such treatment. It is emphasized that “therapeutically effective amount,” administered to a particular subject in a particular instance will not always be effective in treating the diseases described herein, even though such dosage is deemed a “therapeutically effective amount” by those skilled in the art. It is to be further understood that drug dosages are, in particular instances, measured as oral dosages, or with reference to drug levels as measured in blood.
  • Amounts effective for such a use will depend on: the desired therapeutic effect; the potency of the biologically active material; the desired duration of treatment; the stage and severity of the disease being treated; the weight and general state of health of the patient; and the judgment of the prescribing physician. Treatment dosages need to be titrated to optimize safety and efficacy.
  • the appropriate dosage levels for treatment will thus vary depending, in part, upon the indication for which the active agent is being used, the route of administration, and the size (body weight, body surface or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician may titre the dosage and modify the route of administration to obtain the optimal therapeutic effect.
  • a typical dosage may range from about 0.1 mg/kg to up to about 100 mg/kg or more, depending on the factors mentioned above. In other embodiments, the dosage may range from 0.1 mg/kg up to about 100 mg/kg; or 1 mg/kg up to about 100 mg/kg; or 5 mg/kg up to about 100 mg/kg.
  • the frequency of dosing will depend upon the pharmacokinetic parameters of the active agent and the formulation used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect.
  • the composition may therefore be administered as a single dose, or as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via an implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages may be ascertained through use of appropriate dose-response data.
  • a “carrier” can be any solvents, diluents, excipients or other vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • the term "pharmaceutically acceptable carrier” component can refer to a component that is not biologically or otherwise undesirable, i.e., the component may be incorporated into a composition of the invention and administered to a subject as described herein without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the formulation in which it is contained.
  • the component has generally met the required standards of toxicological and manufacturing.
  • the term “subject” generally includes mammals such as: humans; farm animals such as sheep, goats, pigs, cows, horses, llamas; companion animals such as dogs and cats; primates; birds, such as chickens, geese and ducks; fish; and reptiles.
  • the subject is preferably human.
  • the “gastrointestinal tract” refers to the tract from the mouth to the anus which includes all the organs of the digestive system such as the esophagus, stomach, pancreas, liver, gallbladder, small intestine (including the ileum), caecum, large intestine, colon and rectum. Strains of the invention are at least useful for conditions of the terminal ileum, caecum or rectum.
  • a “non-inflammatory strain” refers to a strain of the invention which, when present in the gastrointestinal tract of a subject, preferably a human, is associated with a non-inflamed state.
  • non-inflammatory strains of the invention have little or no cytotoxicity against mammalian cells in culture. In an embodiment, the strain results in less than 15%, less than 10% or less than 5% of cell death of the mammalian cells in culture. In an embodiment, a non-inflammatory strain of the invention causes less cell death when exposed to a given cell type than a strain which comprises a 16S ribosomal RNA (rRNA) gene having a nucleotide sequence as shown in any one of SEQ ID NOs 1-9193, or a nucleotide sequence at least 90% identical to one or more of SEQ ID NOs 1 -9193. In an alternative embodiment, non-inflammatory strains of the invention have some level of cytotoxicity against mammalian cells in culture.
  • rRNA 16S ribosomal RNA
  • an “inflammatory strain” refers to a strain of the invention which, when present in the gastrointestinal tract of a subject, preferably a human, is associated with an inflamed state. Inflammatory strains of the invention have cytotoxicity against mammalian cells in culture. In an embodiment, the strain results at least 40%, at least 45% or at least 50% of cell death of the mammalian cells in culture.
  • an inflammatory strain of the invention causes more cell death when exposed to a given cell type than a strain which comprises a 16S ribosomal RNA (rRNA) gene having a nucleotide sequence as shown in any one of SEQ ID NOs presented in Figure 7 and Figure 8, or a nucleotide sequence at least 90% identical to one or more of SEQ ID NOs presented in Figure 7 and Figure 8.
  • rRNA ribosomal RNA
  • the inflammatory strain of the invention has little to no cytotoxicity against mammalian cells in culture.
  • bacteriotherapy refers to the use of a bacterial isolate to treat or prevent a disease or a condition, or provide a health benefit, in a subject.
  • biotherapeutic refers to a microorganism or combination thereof, such as bacterial isolate, that is useful for treating or preventing a disease or a condition, or provide a health benefit, in a subject.
  • biotherapeutic composition refers to a formulation comprising a biotherapeutic preparation formulated together with one or more additional formulary ingredients to obtain a finished formulation suitable for delivery to a subject.
  • the terms "treat,” “treating,” “treatment” and grammatical variations thereof mean subjecting an individual subject to a protocol, regimen, process or remedy, in which it is desired to obtain a physiologic response or outcome in that subject. Since every treated subject may not respond to a particular treatment protocol, regimen, process or remedy, treating does not require that the desired physiologic response or outcome be achieved in each and every subject or subject population. Accordingly, a given subject or subject population may fail to respond or respond inadequately to treatment.
  • the term “prevent”, “prevented”, or “preventing” when used with respect to the treatment of mucosal inflammation in the gastrointestinal refers to a prophylactic treatment which increases the resistance of a subject to mucosal inflammation in the gastrointestinal, in other words, decreases the likelihood that the subject will develop mucosal inflammation in the gastrointestinal as well as a treatment after mucosal inflammation in the gastrointestinal has begun in order to fight the inflammation, e.g., reduce or eliminate it altogether or prevent it from becoming worse.
  • reducing refers to a reduction but not necessarily a complete abolition of gastrointestinal tract mucosal inflammation in a subject.
  • sample refers to a collection of biological material obtained from a subject or a subject's surrounding environment, such as soil or water in the area that the subject inhabits.
  • the sample is obtained directly from the subject.
  • the sample can be a faecal sample or obtained during a colonoscopy.
  • the sample may be in a form taken directly from the subject or surrounding environment, or it may be at least partially purified to remove at least some non-nucleic acid material. The purification may be slight, for instance amounting to no more than the concentration of the solids, or cells, of the samole into a smaller volume or the separation of cells from some or all of the remainder of the sample.
  • nucleic acids are isolated from the sample. Such isolated preparations include reverse transcription products and/or PCR amplification products of the nucleic acids in the sample. In some embodiments, the predominant nucleic acid is DNA.
  • the nucleic acid preparations can be pure or partially purified nucleic acid preparations. Techniques for the isolation of nucleic acid from samples, including complex samples, are numerous and well known in the art.
  • the unit “cfu” refers to "colony forming unit", which is the number of bacterial cells as revealed by microbiological counts on agar plates.
  • the present invention provides a composition for preventing or treating a gastrointestinal disorder in a subject in need thereof, said composition comprising at least one strain of bacteria.
  • the composition is selected from the group consisting of: a therapeutic composition; a pharmaceutical composition; a cosmetic composition; and a veterinary composition.
  • compositions are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition (which may be for human or animal use).
  • Suitable carriers and diluents include isotonic saline solutions, for example phosphate- buffered saline.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • the composition can contain formulation materials for modifying, maintaining or preserving, for example, the pH, osmolarity, viscosity, clarity, colour, isotonicity, odour, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition.
  • formulation materials for modifying, maintaining or preserving for example, the pH, osmolarity, viscosity, clarity, colour, isotonicity, odour, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition.
  • Suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine or lysine); antimicrobials; antioxidants (such as ascorbic acid, sodium sulphite or sodium hydrogen-sulphite); buffers (such as borate, bicarbonate, Tris-HCI, citrates, phosphates or other organic acids); bulking agents (such as mannitol or glycine); chelating agents (such as ethylenediamine tetra acetic acid (EDTA)); complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin), fillers; monosaccharides, disaccharides; and other carbohydrates (such as glucose, mannose, or dextrins); proteins (such as serum albumin, gelatin or immunoglobulins); colouring, flavouring and diluting agents; emulsifying agents;
  • the optimal composition will be determined by one skilled in the art depending upon, for example, the intended route of administration, delivery format, and desired dosage. Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the biotherapeutic actives of the invention.
  • the preferred form of the pharmaceutical composition depends on the intended mode of administration and therapeutic application.
  • the primary vehicle or carrier in a composition is aqueous in nature.
  • a suitable vehicle or carrier may be water for injection, physiological saline solution, possibly supplemented with other materials.
  • Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles.
  • Other exemplary pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which may further include sorbitol or a suitable substitute thereof.
  • pharmaceutical compositions may be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents in the form of an aqueous solution.
  • the formulation components are present in concentrations that are acceptable to the site of administration.
  • buffers are used to maintain the composition at physiological pH or at a slightly lower pH, typically within a pH range of from about 5 to about 8.
  • compositions will be evident to those skilled in the art, including formulations of the invention in sustained- or controlled-delivery formulations.
  • Techniques for formulating a variety of other sustained- or controlled-delivery means such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art.
  • Additional examples of sustained-sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, for example, films, or microcapsules.
  • Sustained release matrices may include polyesters, hydrogels, polylactides, copolymers of L-glutamic acid and gamma ethyl-L-glutamate, ethylene vinyl acetate or poly- D(-)-3-hydroxybutyric acid.
  • Sustained-release compositions may also include liposomes, which can be prepared by any of several methods known in the art.
  • composition to be used for in vivo administration can be filtered to remove undesirable components. This may be accomplished by filtration through filtration membranes.
  • the compositions generally are placed into a sealed container to reduce exposure to oxygen. Once the pharmaceutical composition has been formulated, it may be stored in sealed containers.
  • % sequence homology may for example be calculated as follows.
  • the query sequence is aligned to the target sequence using the CLUSTAL W algorithm (Thompson et al, Nucleic Acids Research, 22: 4673-4680 (1994)).
  • a comparison is made over the window corresponding to one of the aligned sequences, for example the shortest.
  • the window may in some instances be defined by the target sequence. In other instances, the window may be defined by the query sequence.
  • the nucleic acid residues (nucleotides) at each position are compared, and the percentage of positions in the query sequence that have identical correspondences in the target sequence is reported as % sequence homology, or percent identification.
  • GAP analysis aligns two sequences over their entire length.
  • the bacterial strains for use in the present invention can be cultured using standard microbiology techniques as detailed in, for instance, Handbook of Microbiological Media, Fourth Edition (2010) Ronald Atlas, CRC Press, Maintaining Cultures for Biotechnology and Industry (1996) Jennie C. Hunter-Cevera, Academic Press, as well as how detailed in the Examples using YCFA medium.
  • the composition further comprises water.
  • the composition is a liquid, such as an aqueous solution.
  • composition further comprises a pharmaceutically acceptable carrier.
  • the composition retains its effective biological activity for a period selected from the group consisting of; greater than 24 hours; greater than 36 hours; and greater than 48 hours.
  • the composition is stable for periods selected from the group consisting of: 6 months, 1 year and 2 years.
  • the composition is stable at temperatures selected from the group consisting of: -80°C, -20 °C ,-4°C, 4°C, 18°C and 25°C.
  • compositions are within the scope of the invention.
  • the therapeutic composition of the invention may comprise a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the isolated bacteria present in the therapeutic composition.
  • the precise nature of the pharmaceutically acceptable excipient or other material will depend on the route of administration, which may be, for example, oral or rectal. Many methods for the preparation of therapeutic compositions are known to those skilled in the art (see e.g. Robinson ed., Sustained and Controlled Release Drug Delivery Systems, Marcel Dekker, Inc., New York, 1978).
  • the therapeutic composition of the invention may comprise a prebiotic, an antioxidant, a carrier, insoluble fibre, a buffer, an osmotic agent, an anti-foaming agent and/or a preservative.
  • the therapeutic composition may be made or provided in chemostat medium.
  • the therapeutic composition may be made or provided in saline, e.g., 0.9% saline. It will be understood that any carrier or solution which does not impair viability of the bacteria present in the therapeutic composition and is compatible with administration to an individual may be used.
  • the therapeutic composition may be made or provided under reduced atmosphere, i.e., in the absence of oxygen.
  • a synthetic stool preparation may be made or provided under N2, CO2, H2, or a mixture thereof, optionally with controlled levels of partial pressure of N2:CO2:H2.
  • the therapeutic composition may be for oral or rectal administration to the individual. Where the therapeutic composition is for oral administration, the therapeutic composition may be in the form of a capsule, or a tablet. Where the therapeutic composition is for rectal administration, the therapeutic composition may be in the form of an enema or through colonoscopic delivery.
  • the preparation of suitable capsules, tablets and enema is well-known in the art.
  • the capsule or tablet may comprise a coating to protect the capsule or tablet from stomach acid.
  • the capsule or tablet may be enteric-coated, pH dependent, slow-release, and/or gastro-resistant. Such capsules and tablets are used, for example, to minimize dissolution of the capsule or tablet in the stomach but allow dissolution in the small intestine.
  • Orally dosed formulations can, in addition to the viable microorganisms comprise, inert compression aids, such as microcrystalline cellulose or oligosaccharide, flow aids, such as a silica gel, or a lubricant of, for example magnesium stearate (vegetable source) or stearic acid (vegetable source).
  • inert compression aids such as microcrystalline cellulose or oligosaccharide
  • flow aids such as a silica gel
  • a composition disclosed herein can be used as, for example, a food supplement, an edible product or pharmaceutical product.
  • the composition can further comprise a conventional food supplement filler and/or an extender.
  • the composition disclosed herein can also be included in any edible products, such as dairy products, including for example, a milk product, milk, yogurt, curd, ice-cream, dressing, and cheese, beverage products, meat products, and baked goods
  • Suppository formulations for example, either for rectal use, can in addition to the compositions, comprise, for example, cocoa butter, polyethylene glycol, glycerin or gelatine.
  • the composition may comprise a disintegrant, a glidant, and/or a lubricant.
  • Disintegrants aid in the breakup of the compacted mass when placed in a fluid environment.
  • the disintegrant may be any suitable disintegrant such as for example, a disintegrant selected from the group consisting of sodium croscarmellose, crospovidone, gellan gum, hydroxypropyl cellulose, starch, and sodium starch glycolate.
  • the glidant may be any suitable glidant such as for example, a glidant selected from the group consisting of silicon dioxide, colloidal silicon dioxide, and talc.
  • Lubricants are generally always used in the manufacture of dosage forms by direct compression in order to prevent the compacted powder mass from sticking to the equipment during the tableting or encapsulation process.
  • the lubricant may be any suitable lubricant such as for example, a lubricant selected from the group consisting of calcium stearate, magnesium stearate, stearic acid, sodium stearyl fumarate, and vegetable based fatty acids.
  • the carrier may be present in the composition in a range of approximately 30% w/w to approximately 98% w/w; this weight percentage is a cumulative weight percentage taking into consideration all ingredients present in the carrier.
  • Coatings can be used to control the solubility of the composition. Examples of coatings include carrageenan, cellulose acetate phthalate, ethylcellulose, gellan gum, maltodextrin, methacrylates, methylcellulose, microcrystalline cellulose, and shellac.
  • the composition may comprise one or more preservatives.
  • preservatives include antioxidants, chelating agents, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
  • antioxidants include alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabi sulfite, propionic acid, glutathione, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabi sulfite, and sodium sulfite.
  • Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like), citric acid and salts and hydrates thereof (e.g., citric acid monohydrate), fumaric acid and salts and hydrates thereof, malic acid and salts and hydrates thereof, phosphoric acid and salts and hydrates thereof, and tartaric acid and salts and hydrates thereof.
  • EDTA ethylenediaminetetraacetic acid
  • salts and hydrates thereof e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like
  • citric acid and salts and hydrates thereof e.g., citric acid mono
  • antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
  • Exemplary antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxy benzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
  • Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
  • Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, betacarotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
  • the therapeutic composition may be lyophilized.
  • the lyophilized therapeutic composition may comprise one or more stabilisers and/or cryoprotectants.
  • the lyophilized therapeutic composition may be reconstituted using a suitable diluent prior to administration to the individual.
  • a therapeutic composition according to the present invention may be administered alone or in combination with other treatments, concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of dysbiosis, or a disease associated with dysbiosis as described herein.
  • a strain of the invention may be used in combination with an existing therapeutic agent for inflammatory bowel disease, irritable bowel syndrome, a metabolic disease, a neu'opsychiatric disorder, an autoimmune disease, an allergic disorder, a cancer, or hepatic encephalopathy.
  • the therapeutic composition may optionally be administered in combination with a cancer immunotherapy, such as an immune check-point inhibitor, to the individual.
  • a cancer immunotherapy such as an immune check-point inhibitor
  • check-point inhibitors which may be employed in this context include Programmed cell death protein 1 (PD-1 ) inhibitors, Programmed death-ligand 1 (PD-L1 ) inhibitors, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors.
  • PD-1 Programmed cell death protein 1
  • PD-L1 Programmed death-ligand 1
  • CTL-4 cytotoxic T-lymphocyte-associated protein 4
  • Manipulation of the gut microbiota in combination with immune check-point inhibitor treatment has been shown to improve efficacy of immune check-point inhibitors in treating cancer.
  • the cancer in this context is colorectal cancer.
  • the cancer is renal cancer, lung cancer or melanoma.
  • composition of the invention further comprise immunomodulating compounds.
  • the immunomodulating compound is a cytokine, chemokine, or complement component that enhances expression of immune system accessory or adhesion molecules, their receptors, or combinations thereof.
  • the immunomodulating compound include interleukins, for example interleukins 1 to 15, interferons alpha, beta or gamma, tumour necrosis factor, granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), granulocyte colony stimulating factor (G-CSF), chemokines such as neutrophil activating protein (NAP), macrophage chemoattractant and activating factor (MCAF), RANTES, macrophage inflammatory peptides MIP-1a and MIP-1 b, complement components, or combinations thereof.
  • interleukins for example interleukins 1 to 15, interferons alpha, beta or gamma, tumour necrosis factor, granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), granulocyte colony stimulating factor (G-CSF), chemokines such as neutrophil activating protein (NAP), macrophage chemoat
  • the immunomodulating compound stimulate expression, or enhanced expression of 0X40, OX40L (gp34), lymphotactin, CD40, CD40L, B7.1 , B7.2, TRAP, ICAM-1 , 2 or 3, cytokine receptors, or combination thereof.
  • the immunomodulatory compound induces or enhances expression of co-stimulatory molecules that participate in the immune response, which include, in some embodiments, CD40 or its ligand, CD28, CTLA-4 or a B7 molecule.
  • the immunomodulatory compound induces or enhances expression of a heat stable antigen (HSA), chondroitin sulfate-modified MHC invariant chain (li-CS), or an intracellular adhesion molecule 1 (ICAM-1).
  • HSA heat stable antigen
  • li-CS chondroitin sulfate-modified MHC invariant chain
  • ICM-1 intracellular adhesion molecule 1
  • the therapeutic compositions of the invention may be administered to an individual, preferably a human individual. Administration may be in a "therapeutically effective amount", this being sufficient to show benefit to the individual. Such benefit may be at least improvement or amelioration of at least one symptom. Thus “treatment” of a specified disease refers to amelioration of at least one symptom.
  • the actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated, the particular patient being treated, the clinical condition of the individual patient, the cause of the dysbiosis, the site of delivery of the composition, the type of therapeutic composition, the method of administration, the scheduling of administration and other factors known to medical practitioners. Prescription of treatment, e.g.
  • a therapeutically effective amount or suitable dose of a therapeutic composition of the invention can be determined by comparing its in vitro activity and in vivo activity in an animal model. Methods for extrapolation of effective dosages in mice and other test animals to humans are known. The precise dose will depend upon a number of factors, including whether the therapeutic composition is for prevention or for treatment.
  • Formulary ingredients can be contacted with the preparation and mixed or prepared until a formulation is obtained.
  • formulation conditions will generally be such that viable microorganisms are retained. In particular high temperatures, for example temperatures in excess of 40°C are avoided.
  • the amount of viable microorganisms included in a composition can vary and can be adjusted and optimized as will be appreciated by those of skill in the art. Such optimization may, for example, be achieved by preparing a series of different doses of a viable microorganism.
  • the bacterial concentration in the composition can be, for example, from 10 1 cfu/mL to 10 16 cfu/mL, 1 cfu/mL to 10 cfu/mL, 100 cfu/mL to 1 thousand cfu/mL, 10 thousand cfu/mL to 100 thousand cfu/mL, 1 million cfu/mL to 10 million cfu/mL, from 10 million cfu/mL to 100 billion cfu/mL, from 10 million to 50 million cfu/mL, more preferably from 50 million to 100 million cfu/mL, from 100 million to 500 million cfu/mL, from 500 million to 1 billion cfu/mL, from 1 billion to 5 billion cfu/mL, from 5 billion to 10 billion cfu/mL, from 10 billion to 15 billion cfu/mL, from 15 billion to 20 billion cfu/mL, from 20 billion to 25 billion
  • the strain of the invention can be administered at, for example, a dosage of 0.01 to 100 x 10 11 cells/body, 0.1 to 10 x 10 11 cells/body or 0.3 to 5 x 10 11 cells/body.
  • the amount ingested per day as the bacteria can be 0.01 to 100 x 10 11 cells/60 kg body weight, 0.1 to 10 x 10 11 cells/60 kg body weight or 0.3 to 5 x 10 11 cells/60 kg body weight.
  • the content of at least one strain of bacteria contained in the orally ingested composition of the present invention may be determined as appropriate depending on its application form.
  • a dry microbial body it can be, for example, 5 to 50 w/w %, 1 to 75 w/w %, 0.1 to 100 w/w % or 1 to 100 w/w %.
  • the composition is a controlled-release composition.
  • controlled-release refers to release or administration of a strain of the invention from a given dosage form in a controlled fashion in order to achieve the desired pharmacokinetic profile in vivo.
  • An aspect of "controlled” delivery is the ability to manipulate the formulation and/or dosage form in order to establish the desired kinetics of release.
  • Procedures for preparing tablets, caplets, capsules and other forms of compositions of the invention are known to those of ordinary skill in the art and include without limitation wet granulation, dry granulation, and direct compression (for tablets and caplets).
  • a chilsonation is used to manufacture the powder for the dosage forms.
  • a chilsonator houses grooved, rotating rollers that are pressed tightly against one another by hydraulic pressure.
  • Raw materials are placed into the hopper of the chilsonator and are fed by a system of horizontal and vertical screws into the rollers.
  • the sheets are milled into a fine granular powder using a Fitz mill and then passed through a screen to produce a uniform free flowing granule.
  • the chilsonation process results in a finished powder that is two to four times denser than the starting material, a feature that permits the ingredients to be fashioned into the desired dosage form.
  • the powder With dry granulation, the powder may be incorporated into a gelatin capsule or it may be mixed with gelatin to form a tablet or caplet. With wet granulation, the powder is moistened thus creating large "chunks" of material that are subsequently dried and milled to convert the chunks to particles of a desired size for the manufacturing process. Once the particles of a desired size are obtained, the particles are incorporated into a gelatin capsule or mixed with gelatin to form a tablet or caplet.
  • a composition of the invention can comprise a prebiotic. Because prebiotics have a chemical structure that resists digestion through the alimentary tract, they reach the colon as intact molecules where they are able to elicit systemic physiological functions and act as fermentable substrates for colonic microflora. Where a prebiotic is combined with a biotherapeutic, the resulting composition is sometimes referred to as a "synbiotic.”
  • oligosaccharide such as fructooligosaccharides, P95 Nutraflora®, for example, galactooligosaccharides, xylooligosaccharides, isomaltooligosaccharides, quercetin, human milk oligosaccharides, inulin oligosaccharides, mannan oligosaccharides, pyrodextrin, levan, maltotriose, pectic oligosaccharides, bimuno-galactooligosaccharides, arabinoxylan, fucoidan and resistant starches.
  • Fructooligosaccharides can be extracted from, for example, chicory, artichokes, asparagus, dandelions, dahlias, endive, garlic, leeks, lettuce, and onions.
  • the prebiotic comprises amino acids such as one or more or all of alanine, aspartic acid, glutamic acid, glycine, leucine, isoleucine, proline, serine, threonine and valine.
  • the prebiotic comprises simple sugars which can be a monosaccharide (such as glucose, galactose or fructose) and/or a disaccharide (such as sucrose maltose or lactose).
  • a monosaccharide such as glucose, galactose or fructose
  • a disaccharide such as sucrose maltose or lactose
  • the prebiotic comprises from about 0.01 % (w/w) to about 75% (w/w), 5% (w/w) to about 50% (w/w), about 7.5% (w/w) to about 30% (w/w) or about 10% (w/w) to about 15% (w/w) of the composition.
  • the composition may comprise more than one species/strain of microorganisms in addition to the strain of the invention, such as two, three, four, five or a higher plurality of species/strains of microorganisms.
  • biotherapeutics are suitable strains of the genera Absiella, Acetobacterium, Adlercreutzia, Aerococcus, Agathobaculum, Akkermansia, Alistipes, Allobaculum, Amedibacterium, Anaerobutyricum, Anaerofustis, Anaerostipes, Anaerotignum, Anaerotruncus, Bacillus, Bacteroides, Barnesiella, Bifidobacterium, Blautia, Butyricimonas, Carnobacterium, Christensenella, Ciostridium, Collinsella, Coprobacillus, Coprobacter, Coprococcus, Dorea, Enorma, Enterocloster, Enterococcus, Erysipelatoclostridium, Escherichia, Eubacterium, Faecalibacillus, Faecalibacterium, Finegoldia, Flavonifractor, Flintibacter, Gemmiger, Holdemanella, Hungatella,
  • biotherapeutics that may be included in the composition of the present invention.
  • any additional biotherapeutic species may also be used in the compositions of the present invention.
  • yeasts are also useful as biotherapeutics and are sometimes included in the compositions.
  • One non-limiting example of a yeast used in biotherapeutics is Saccharomyces boulardii.
  • Some archaea are also useful as biotherapeutics and are sometimes included in the compositions.
  • Non-limiting examples of an archaea used in biotherapeutics is Methanobrevibacter spp, including Methanobrevibacter smithii and Methanosphaera sp, including Methanobrevibacter stadtmanae.
  • Dosage forms are within the scope of the invention.
  • the invention provides a dosage form comprising the composition as described in the first aspect of this invention.
  • the dosage form is stored in a sealed and sterile container.
  • Method for treating a gastrointestinal disorder are within the scope of the invention.
  • the invention provides a method for treating a gastrointestinal disorder, wherein said method comprises the administration to a patient in need thereof a therapeutically effective amount of the composition as described in the first aspect of this invention.
  • the dosage form is administered at an amount to at least partially treat a gastrointestinal disorder.
  • a subject that can be treated with the invention will include humans as well as other mammals and animals.
  • the effect of the administered therapeutic composition can be monitored by standard diagnostic procedures.
  • Methods of the invention can be used to treat or prevent a dysbiosis of the gastrointestinal tract in a subject.
  • Dysbiosis in the context of the present invention refers to a state in which the normal diversity, relative proportions of species and/or function of the microbiota or microbiome, in particular the human gastrointestinal microbiota, is disrupted. Any disruption from the normal state of the microbiota in a healthy individual can be considered a dysbiosis, even if the dysbiosis does not result in a detectable decrease in health in the individual.
  • the dysbiosis may be associated with one or more pathological symptoms.
  • dysbiosis may refer to a decrease in the microbial diversity of the microbiota.
  • “dysbiosis” may refer to an increase in the abundance of one or more bacteria, e.g. one or more pathogenic bacteria, in the microbiota of an individual relative to the abundance of said bacterium or bacteria in the microbiota of a healthy individual, i.e. an individual without a dysbiosis.
  • the pathogenic bacteria present during dysbiosis are often Proteobacteria and resistant to one or more antibiotics. Examples of Proteobacteria include Escherichia, Salmonella, Campylobacter, Vibrio, Helicobacter, and Yersinia species.
  • the dysbiosis may be a dysbiosis associated with an enteric bacterial infection, such as an infection of the gastrointestinal tract with a pathogenic bacterium.
  • Many bacteria capable of causing infections of the gastrointestinal tract in humans are known and include: gram positive bacteria, and gram negative bacteria.
  • the pathogenic bacterium is preferably a pathogenic species of the genus Clostridium, Escherichia, Enterococcus, Klebsiella, Enterobacter, Proteus, Salmonella, Shigella, Staphylococcus, Vibrio, Aeromonas, Campylobacter, Plesiomonas, Bacillus, Helicobacter, Listeria, or Yersinia.
  • pathogenic bacteria include Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Escherichia coli, Salmonella typhi, Staphylococcus aureus, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificus, Campylobacter fetus, Campylobacter jejuni, Aeromonas hydrophila, Plesiomonas shigelloides, Bacillus cereus, Helicobacter pylori, Listeria monocytogenes, and Yersinia enterocolitica. More preferably, the pathogenic bacterium is a pathogenic species of the genus Clostridium or Escherichia. Most preferably, the pathogenic bacterium is Clostridium difficile or Escherichia coli.
  • Methods of the invention can be used to reduce or prevent gastrointestinal tract mucosal inflammation in a subject using compositions of the invention.
  • the subject has, or is susceptible to having, an inflammatory bowel disease (IBD) such as Crohn's disease, ulcerative colitis and pouchitis.
  • IBD inflammatory bowel diseases
  • the term "inflammatory bowel diseases (IBD)” has its general meaning in the art and refers to a group of inflammatory diseases of the colon and small intestine such as revised in the World Health Organisation Classification K20-K93 (ICD-10) such as Crohn disease (such as granulomatous enteritis; Crohn disease of small intestine; Crohn disease of large intestine; granulomatous and regional Colitis; Crohn disease of colon, large bowel and rectum; Crohn disease of both small and large intestine), Ulcerative colitis (such as Ulcerative (chronic) pancolitis; backwash ileitis; Ulcerative (chronic) proctitis; Ulcerative (chronic) rectosigmoiditis; Inflammatory polyps; Left sided colitis; left hemicolitis) and nonin
  • the present invention also relates to a faecal microbiota transplant composition comprising the strain of the invention.
  • faecal microbiota transplant composition has its general meaning in the art and refers to any composition that can restore the faecal microbiota.
  • Administration to humans includes administration by a medical professional and self-administration.
  • single or multiple doses of the composition are administered, for example once-off, daily for a period of at least one week, at least two weeks, at least three weeks, at least six weeks, at least nine weeks, or at least twelve weeks.
  • the compositions can be administered for the remaining duration of a subject's life.
  • the invention provides a device, wherein the device comprises: (1 ) the composition as described in the first aspect of this invention; and (2) an applicator, container or material.
  • the invention provides the use of a composition in the manufacture of a medicament for treating a gastrointestinal disorder.
  • the said method protects the compositions of the invention against degradation.
  • composition of the invention retains its effective biological activity for a period selected from the group consisting of; greater than 24 hours; greater than 36 hours; greater than 48 hours.
  • compositions of the invention solutions are preferred from a safety standpoint, as the simpler methodology is likely to produce a less variable outcome and the choice of excipient can be limited to those with Generally Regarded as Safe (GRAS) status.
  • Excipients for the stabilisation of protein solutions can be classified into four broad categories: salts, sugars, polymers or protein/amino acids, based on their chemical properties and mechanism of action. Salts (e.g. chlorides, nitrates) stabilise the tertiary structure of proteins by shielding charges through ionic interactions.
  • Sugars e.g.
  • glycerol, sorbitol, fructose, trehalose increase the surface tension and viscosity of the solution to prevent protein aggregation.
  • polymers e.g. polyethylene glycol, cellulose derivatives
  • stabilise the protein tertiary structure by increasing the viscosity of the solution to prevent protein aggregation and intra- and inter-molecular electrostatic interactions between amino acids in the protein.
  • Proteins e.g. human serum albumin
  • small amino acids with no net charge, such as alanine and glycine stabilise proteins through the formation of weak electrostatic interactions.
  • the medicaments of the present invention may include one or more pharmaceutically acceptable carriers.
  • pharmaceutically acceptable carriers may include one or more of the following examples: a.
  • surfactants and polymers including, however not limited to, polyethylene glycol (PEG), polyvinylpyrrolidone , polyvinylalcohol, crospovidone, polyvinylpyrrolidone-polyvinylacrylate copolymer, cellulose derivatives, HPMC, hydroxypropyl cellulose, carboxymethylethyl cellulose, hydroxypropylmethyl cellulose phthalate, polyacrylates and polymethacrylates, urea, sugars, polyols, and their polymers, emulsifiers, sugar gum, starch, organic acids and their salts, vinyl pyrrolidone and vinyl acetate; and/or b.
  • PEG polyethylene glycol
  • polyvinylpyrrolidone polyvinylalcohol
  • crospovidone polyvinylpyrrolidone-polyvinylacrylate copolymer
  • cellulose derivatives HPMC, hydroxypropyl cellulose, carboxymethylethyl cellulose,
  • binding agents such as various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose; and/or (3) filling agents such as lactose monohydrate, lactose anhydrous, microcrystalline cellulose and various starches; and/or c. filling agents such as lactose monohydrate, lactose anhydrous, mannitol, microcrystalline cellulose and various starches; and/or d. lubricating agents such as agents that act on the increased ability of the dosage form to be ejected from the packaging cavity, and/or e.
  • sweeteners such as any natural or artificial sweetener including sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acesulfame K; and/or f. flavouring agents; and/or g. preservatives such as potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxy benzoic acid such as butyl paraben, alcohols such as ethyl or benzyl alcohol, phenolic chemicals such as phenol, or quarternary compounds such as benzalkonium chloride; and/or h. buffers; and/or i.
  • preservatives such as potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxy benzoic acid such as butyl paraben, alcohols such as ethyl or benzyl alcohol, phenolic chemicals such as phenol, or quarternary
  • diluents such as pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing; and/or j. absorption enhancer such as glyceryl trinitrate; and/or k. other pharmaceutically acceptable excipients.
  • pharmaceutically acceptable inert fillers such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing
  • absorption enhancer such as glyceryl trinitrate
  • k other pharmaceutically acceptable excipients.
  • Medicaments of the invention suitable for use in animals and in particular in human beings typically must be sterile and stable under the conditions of manufacture and storage.
  • a strain of the invention can be detected using a wide variety of known techniques. Conveniently the strain is detected using a nucleic acid-based detection system.
  • nucleic acid sequencing is used.
  • Illustrative non-limiting examples of nucleic acid sequencing techniques include, but are not limited to, chain terminator (Sanger) sequencing and dye terminator sequencing.
  • the technology provided herein finds use in a Second Generation (a.k.a. Next Generation or Next- Gen), Third Generation (a.k.a. Next-Next-Gen), or Fourth Generation (a.k.a. N3-Gen) sequencing technology including, but not limited to, pyrosequencing, sequencing-by-ligation, single molecule sequencing, sequence-by-synthesis (SBS), massive parallel clonal, massive parallel single molecule SBS, massive parallel single molecule real-time, massive parallel single molecule real-time nanopore technology.
  • SBS sequence-by-synthesis
  • hybridization is employed in a detection method of the invention.
  • nucleic acid hybridization techniques include, but are not limited to, in situ hybridization (ISH), microarray, and Southern or Northern blot.
  • ISH in situ hybridization
  • FISH FISH assay
  • nucleic acid amplification is used. Nucleic acids may be amplified prior to or simultaneous with detection. Conducting one or more amplification reactions may comprise one or more PCR-based amplifications, non- PCR based amplifications, or a combination thereof.
  • nucleic acid amplification techniques include, but are not limited to, polymerase chain reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), nested PCR, linear amplification, multiple displacement amplification (MDA), real-time SDA, rolling circle amplification, circle-to-circle amplification transcription-mediated amplification (TMA), ligase chain reaction (LCR), strand displacement amplification (SDA), and nucleic acid sequence based amplification (NASBA).
  • PCR polymerase chain reaction
  • RT-PCR reverse transcription polymerase chain reaction
  • MDA multiple displacement amplification
  • TMA circle-to-circle amplification transcription-mediated amplification
  • LCR ligase chain reaction
  • SDA strand displacement amplification
  • NASBA nucleic acid sequence based amplification
  • RNA be reversed transcribed to DNA prior to amplification e.g., RT-PCR
  • other amplification techniques directly amplify RNA (e.g., TMA and NASBA).
  • Non-amplified or amplified nucleic acids can be detected by any conventional means.
  • the nucleic acids can be detected by hybridization with a detectably labeled probe and measurement of the resulting hybrids.
  • the nucleic acids are detected by sequencing. Illustrative non-limiting examples of detection methods are described herein.
  • Evaluation of an amplification process in "real-time” involves determining the amount of amplicon in the reaction mixture either continuously or periodically during the amplification reaction and using the determined values to calculate the amount of target sequence initially present in the sample.
  • a variety of methods for determining the amount of initial target sequence present in a sample based on real-time amplification are well known in the art. These include methods disclosed in U.S. Pat. Nos. 6,303,305 and 6,541 ,205.
  • Another method for determining the quantity of target sequence initially present in a sample, but which is not based on a real-time amplification, is disclosed in U.S. Pat. No. 5,710,029.
  • Amplification products may be detected n real time through a combination of primers specific to the region of interest and a non-specific fluorescent DNA binding dye.
  • primers are designed so that they specifically target a region unique to the microbe of interest, leading to amplification of only the designed target.
  • the primer design incorporates two individual primers that complementarily bind up and downstream of the targeted DNA site. During amplification the primers will bind up and downstream of the target of interest, generating an additional copy through polymerase chain reaction, with the DNA-binding dye being incorporated into the newly generated amplicon. Post amplification, the DNA-binding dye is excited via a specific wavelength of light and the emission at a different wavelength is measured.
  • Binding of the fluorescent DNA-bindinc dye to the exponentially increasing amplicon of interest can be correlated with standards of known concentration through linear regression to determine the original copy number of the target region amplified.
  • the methodology of using DNA-binding dyes is disclosed n U.S. Pat. No. 6,174,670.
  • the specific use of the fluorescent DNA-binding dye SYBR green I is disclosed in U.S. Pat. No. 5,338,671 and 5,587,287.
  • Amplification products may be detected in real-time through the use of various self-hybridizing probes, most of which have a stem-loop structure.
  • Such self-hybridizing probes are labeled so that they emit differently detectable signals, depending on whether the probes are in a self-hybridized state or an altered state through hybridization to a target sequence.
  • “molecular torches” are a type of self-hybridizing probe that includes distinct regions of self-complementarity (referred to as “the target binding domain” and “the target closing domain") which are connected by a joining region (e.g., nonnucleotide linker) and which hybridize to each other under predetermined hybridization assay conditions.
  • molecular torches contain single-stranded base regions in the target binding domain that are from 1 to about 20 bases in length and are accessible for hybridization to a target sequence present in an amplification reaction under strand displacement conditions.
  • hybridization of the two complementary regions, which may be fully or partially complementary, of the molecular torch is favored, except in the presence of the target sequence, which will bind to the singlestranded region present in the target binding domain and displace all or a portion of the target closing domain.
  • the target binding domain and the target closing domain of a molecular torch include a detectable label or a pair of interacting labels (e g., luminescent/quencher) positioned so that a different signal is produced when the molecular torch is self-hybridized than when the molecular torch is hybridized to the target sequence, thereby permitting detection of probe- -target duplexes in a test sample in the presence of unhybridized molecular torches.
  • a detectable label or a pair of interacting labels e g., luminescent/quencher
  • Molecular beacons include nucleic acid molecules having a target complementary sequence, an affinity pair (or nucleic acid arms) holding the probe in a closed conformation in the absence of a target sequence present in an amplification reaction, and a label pair that interacts when the probe is in a closed conformation. Hybridization of the target sequence and the target complementary sequence separates the members of the affinity pair, thereby shifting the probe to an open conformation. The shift to the open conformation is detectable due to reduced interaction of the label pair, which may be, for example, a fluorophore and a quencher (e.g., DABCYL and 25 EDANS). Molecular beacons are disclosed in U.S. Pat. Nos. 5,925,517 and 6,150,097.
  • the method includes quantifying the amount of strain present in the sample
  • the aim of the therapy is to induce and maintain remission by reducing sulphide levels in the colon of patients with ulcerative colitis Materials, Methods and Results
  • compositions of this invention targets the proximal cause of colonocyte barrier disruption that results in immune activation.
  • Reducing luminal sulphide can be accomplished by “turning off the tap” of sulphide production or by removing sulphide from the colon. Each of these mechanisms can be targeted using a live biotherapeutic product.
  • Sulphidogenic microbiota use specific substrates for metabolism.
  • SRB sulphate-reducing bacteria
  • Non-sulphidogenic microbiota which utilise these substrates, compete with sulphidogenic microbiota; such competition would limit the growth of sulphidogenic microbiota and lessen the production of luminal sulphide.
  • Microbiota also compete with sulphidogenic organisms for electron acceptors.
  • H2 molecular hydrogen
  • Methanogenic archaea and/or acetogenic bacteria divert hydrogen (H 2 ) away from sulphidogenic microbiota via competitive H 2 uptake.
  • Reducing luminal sulphide can be accomplished by competitive H 2 uptake by methanogenic archaea, acetogenic bacteria or other microorganisms (Smith, N. W., Shorten, P. R., Altermann, E., Roy, N. C. & McNabb, W. C. Competition for Hydrogen Prevents Coexistence of Human Gastrointestinal Hydrogenotrophs in Continuous Culture. Front. Microbiol. 11 , 1073 (2020)).
  • Methanogenic archaea such as Methanobrevibacter smithii and acetogenic bacteria such as Alistipes spp., Blauti spp.and Roseburia spp. are diminished in ulcerative colitis and associated with clinical remission in FMT.
  • Figure 2 shows a diagrammatic representation of hydrogen uptake by acetogens and methanogens that reduce sulphide production by SRB. Competition for metabolic substrates necessary for the growth and/or metabolism of sulphidogenic microbiota offers a therapeutic target to reduce endogenous sulphide in the colon.
  • Sulphidogenic microbiota require sulphur substrates (such as inorganic sulphate, sulphite, thiosulphate, and tetrathionate, and organic cysteine, methionine, and taurine) to produce sulphide.
  • substrates such as inorganic sulphate, sulphite, thiosulphate, and tetrathionate, and organic cysteine, methionine, and taurine
  • these substrates come from, but are not limited to, dietary sulphur sources, such as meat and cruciferous vegetables, host mucin, bile acids, and endogenous proteins (Wolf, P. G. et al. Diversity and distribution of sulphur metabolism in the human gut microbiome and its association with colorectal cancer.
  • sulphur is ubiquitously present in the colon, much of it is bound in complex molecules inaccessible to sulphidogenic microbiota.
  • other microbiota are often required to biotransform these compounds into accessible forms.
  • SRB depend on saccharolytic bacteria, such as Bacteroides spp., to remove sulphate from host mucin (Tsai, H. H., Sunderland, D., Gibson, G. R., Hart, C. A. & Rhodes, J. M.
  • colonic bacteria ferment carbohydrates in preference to protein in the human colon and thus adequate amounts of dietary fibre reduce the amount of sulphur-containing amino acids released into the colon.
  • a high protein diet results in faecal microbiota changes that increase sulphide production and decrease SCFA production (Teigen, L. M. et al. Dietary Factors in Sulfur Metabolism and Pathogenesis of Ulcerative Colitis. Nutrients 11, (2019)).
  • dietary fibres have been demonstrated to attenuate sulphide gas production in bioreactors containing stool from ulcerative colitis patients (Yao, C. K. et al.
  • Bacterial species can consume sulphide thereby reducing colonic sulphide levels.
  • An example of sulphide consumption is through assimilation of sulphide to cysteine.
  • Cysteine is synthesized from serine in a two-step process, commencing with transfer of the acetyl group from acetyl-CoA to serine, forming O-acetylserine (OAS), catalyzed by serine acetyltransferase (SAT).
  • OAS O-acetylserine
  • SAT serine acetyltransferase
  • the second step a condensation of OAS with sulphide to yield cysteine and acetate, catalyzed by O-acetylserine(thiol)lyase (OASTL) (Figure 4).
  • Direct consumption i.e., the biotransformation of sulphide, either metabolically or otherwise, can therefore reduce colonic levels of sulph
  • BB265 is an encapsulated bioreactor-derived microbial consortium comprising specific microbial strains that reduce colonic sulphide which drives the onset of the chemical lesion seen in ulcerative colitis and can optionally include a collection of the globally most prevalent taxa or isolates (global core microbiome), taxa or isolates which best discriminate between health and ulcerative colitis, keystone taxa or isolates, and phylogenetically diverse taxa or isolates.
  • the BB265 drug discovery process detailing lead selection and validation prior to consortium validation in a phase 1 study is presented in Figure 3.
  • Colonic microorganisms live in an ecosystem with many syntrophic relationships. Individual strains require many other species to sustain them via synergistic interactions. Keystone species are those that have a particularly critical role for the survival of many other species in the ecosystem, and in ecosystem stability and have outsized importance on the ecosystem often through uniquely held functions or functions that have limited redundancy within the system. (Banerjee, S., Schlaeppi, K. & van der Heijden, M. G. A. Keystone taxa as drivers of microbiome structure and functioning. Nat. Rev. Microbiol. 16, 567-576 (2016)). In addition, keystone species are also those linked with clinical efficacy, identified by their presence as a predictive factor for whole community recovery post-antibiotic treatment.
  • the inventors performed a global metagenomic meta-analysis to identify the most prevalent species shared across different geographical regions. This global core microbiome was then supplemented with the addition of previously identified keystone species and those identified informatically as keystones through multi-correlative network analysis. These bacterial isolates were drawn from the inventor’s culture collection and progressed to pilot process development to co-culture the defined community of species in bioreactors. This community supports the defined therapeutic candidate organisms, disrupts the existing community, and provides therapeutic potential themselves given the community contains many health associated organisms and has the emergent property of bolstering the effect of sulphide reduction by candidate microorganisms in ulcerative colitis.
  • Bacteria or archaea with the following characteristics were identified as Leads considered for inclusion in the BB265 complex consortium: (1 ) globally prevalent taxa or isolates commonly found in healthy human faecal microbiomes, (2) taxa or isolates that best discriminate between the faecal microbiomes of health and ulcerative colitis (health associated), (3) keystone taxa or isolates, (4) phylogenetically diverse taxa or isolates, (5) sulphide consuming (or assimilating) taxa or isolates, (6) putative H2 consuming taxa or isolates such as methanogenic archaea and homoacetogenic bacteria, and (7) taxa or isolates that divert metabolic substrates away from sulphide production.
  • Bacteria or archaea with the following characteristics were identified as Targets considered for exclusion from the BB265 complex consortium: (1) taxa or isolates that best discriminate between the faecal microbiomes of health and ulcerative colitis (disease- associated), (2) and taxa or isolates identified as sulphidogens.
  • the inventors have developed unique phenotypic assays that identify sulphide producing microbial isolates; the inventor’s bacterial culture collection has been screened for sulphide production.
  • the inventors have additionally developed unique phenotypic assays that identify sulphide consuming (or assimilating) microbial isolates; isolates identified as Leads with the ability to consume sulphide were considered candidate therapeutic organisms.
  • Unique phenotypic assays were developed to quantify sulphide production by the community, this was paired with measurements of real-time rates of production of H2S using H2S-specific commercial electrochemical sensors.
  • the inventors further supported the mechanism of action of BB265 by identifying an increase in taxa comprising the BB265 consortium in patients with active ulcerative colitis who successfully went into remission due to receiving faecal microbiota transplantation in a randomized, controlled trial.
  • This increase in BB265-associated taxa with remission was paired with a decrease in taxa identified as putative sulphidogens, supporting the hypothesis of sulphide reduction as a therapeutic target.
  • the inventors assayed stool from patients prior to receiving faecal microbiota transplantation and then from stool post remission and identified a significant reduction in the sulphide-producing capacity of the community post-remission.
  • the final candidate consortium will be further tested in a phase 1 human trial.
  • This final drug product will contain the enriched bacterial strains which target the underlying cause of the metabolic lesions in ulcerative colitis, further supported by a community comprising the most prevalent bacteria in healthy humans globally in addition to known keystone species that sustain important synergistic links in the colonic ecosystem.
  • the phase 1 human trial will show that the inventor’s live biotherapeutic product acts early in the disease pathway to prevent barrier disruption by limiting the NO- and H2S-induced metabolic lesion.
  • the phase 1 human trial will have the ability to assess important mechanistic endpoints e.g. therapeutic candidate’s ability to reduce sulphide in a patient with ulcerative colitis.
  • MPC 'Most Prevalent Community
  • Microbial species found to be globally prevalent in healthy human faecal microbiomes were determined via publicly available Illumina paired-end shotgun metagenomes from faeces of individuals with a reported healthy phenotype downloaded from the European Nucleotide Archive (ENA). This analysis resulted in the generation of priority lists from 1 to 2, and 4 to 6 depending on global span and read coverage. Metagenomes with over five million reads were retained and the 882 remaining metagenomes were assigned to geographic regions based on their origin, including Africa, South America, North America, Europe and Asia-Pacific.
  • Sequenced reads were trimmed using Trimmomatic version 0.39 and taxonomic classification was performed using Kraken version 2.1.2 through comparison to a custom database built from all available complete genomes in the National Center for Biotechnology Information (NCBI) Reference Sequence Database (RefSeq release 209). Reads mapping to Homo sapiens were removed and low abundance taxa with less than 0.001 % of total reads were removed to filter out spurious read classifications from each sample.
  • NCBI National Center for Biotechnology Information
  • CO-OCCURRENCE INFORMED MOST PREVALENT COMMUNITY COIMPC
  • Microbial communities contain a plethora of complex interactions both between and within species and these synergistic relationships are integral to a functioning ecosystem (Sharon, I. et al. The Core Human Microbiome: Does It Exist and How Can We Find It? A Critical Review of the Concept. Nutrients 14, (2022)).
  • One way of considering these interactions is via co-occurrence analyses.
  • a co-occurrence informed; most prevalent community structure approach overlays co-occurrence data onto the prevalence data to maximise the likelihood of forming functional communities.
  • Co-occurrence suggests a mutually beneficial relationship among bacteria of the MPC and more globally transient bacteria.
  • Bioinformatic analyses were performed to identify species co-occurring with globally prevalent species in the complex consortium. Specifically, network analysis was performed on the global metagenomic classification output with SpiecEasi v1.1.2 using Meinshausen-Buhlmann neighbourhood selection with 50 repetitions of the Stability Approach to Regularisation Selection (StARS), an nlambda value of 20 and a lambda. min.ratio of 0.01 . Species directly connected in the network to existing MPC taxa were selected for inclusion in the consortium based on this co-occurrence. These species have statistically inferred interactions with the complex consortium taxa, which implies a supportive role in the community.
  • StARS Stability Approach to Regularisation Selection
  • Microbial taxa have varying levels of connectivity within their ecological community, with some taxa contributing more to community functioning and stability than others, referred to as hubs. Hubs have a high level of connectivity to other community members and are often essential for community structure and metabolic cycling (Banerjee, S., Schlaeppi, K. & van der Heijden, M. G. A. Keystone taxa as drivers of microbiome structure and functioning. Nat. Rev. Microbiol. 16, 567-576 (2018)). A method of identifying hub taxa in the gastrointestinal microbiome is through network analyses of sequencing data. Hubs are defined by their level of connectedness to other nodes in the network, inferring their importance in community functioning.
  • Bioinformatic network analyses were performed to identify statistically inferred hubs in the global metagenomic classification output. These analyses were performed using SpiecEasi with Meinshausen-Buhlmann neighbourhood selection and NetCOMI with SPRING association estimation, to identify taxa with the highest degree of centrality. These methods identify nodes with the highest connectivity, determining potential hubs within the network. Taxa identified as hubs, with high closeness, betweenness or eigenvector centrality were selected for inclusion. The species identified through these methods may have key roles in community structure determination and metabolic precesses.
  • 16S rRNA gene sequence-based similarity comparisons were used to identify culture collection isolates from BiomeBank that were phylogenetically distinct from the existing complex consortium. Isolates with a 16S sequence less than 98% identity, determined by NCBI-BLAST (blastn) (v2.13.0) comparison to any species or strain in the consortium, were iteratively included as they may fill ecological niches not covered by the initial community. Phylogenetic analyses were performed to evaluate phylogenetic coverage of the complex consortium with the addition of these diversity inclusion isolates.
  • Faecal microbiota transplant has emerged as a potential treatment for ulcerative colitis, showing induction of remission in UC patients ).
  • the clinical success of FMT is varied, possibly due to variation in preparation, delivery and donor . Since some donors have a greater observed success in recipient remission , it has been suggested that diversity or the presence of a specific combination of microbes may be responsible.
  • this analysis aims to define a consortium of taxa that discern between active UC, and healthy controls from a diverse array of publicly available faecal metagenomes, for the purpose of determining microbial targets associated with disease, or therapeutic bacteria and communities for disease treatment.
  • the resulting kraken2 report files were input into Bracken for read count correction (Lu, J., Breitwieser, F. P., Thielen, P. & Salzberg, S. L. Bracken: estimating species abundance in metagenomics data. PeerJ Comput. Sci. 3, e104 (2017)). Any read counts below 0.001 % per sample were removed to reduce bias by spurious read assignment during classification. A data table was created through merging individual sample bracken outputs.
  • a phyloseq object was created from the filtered bracken outputs and sample metadata, used for input into the ANCOM-BC R package.
  • the ancombc function was run with default parameters, except with the inclusion of structural zeros and the neg_lb parameter set to true, and a conservative variance estimate (conserve set to true), as well as performing the global test.
  • Resulting Holm-Bonferroni adjusted p values were used to identify statistically significant differentially abundant taxa (p ⁇ 0.05)
  • Filtered bracken outputs were input into the R package selbal to determine taxa associated with metadata groups.
  • the cross-validation function, selbal.cv, was run with ten iterations to identify components of the balance, or group of taxa, that form the inferred microbiome signature of each metadata group.
  • Fresh faecal samples were transferred to a Whitley A55 HEPA Anaerobic Workstation (Don Whitley Scientific) (atmosphere: 10% H2, 10% CO2, 80% N2) within 1 hour of donation, mixed with pre-reduced phosphate-buffered saline (PBS) to a concentration of 100 mg/mL and homogenised via vortex mixing for 5 min. Faecal homogenates were then serially diluted in sterile, pre-reduced PBS, spread plated onto multiple broad-range and selective bacteriological mediamedia and incubated anaerobically at 37 °C for 24-168 hours.
  • PBS phosphate-buffered saline
  • Raw sequence data output from capillary sequencing were quality filtered to remove reads containing ⁇ 600 bases total with a Phred quality score ⁇ 20. Quality filtered sequence chromatograms were then visually inspected to ensure purity of the sample. Forward and reverse paired-end reads were then merged using PEAR run by default settings. Merged reads were then trimmed left and right by 60 bp each to remove low quality bases.
  • NCBI-BLAST (blastn) (v2.13.0) was then performed on merged sequences against the NCBI RefSeq 16S rRNA database (RefSeq release 209) and 16S databases constructed in-house comprising representatives of (1 ) globally prevalent taxa or isolates commonly found in healthy human faecal microbiomes, (2) taxa or isolates that best discriminate between the faecal microbiomes of health and ulcerative colitis (health associated), (3) keystone taxa or isolates, and (4) putative Hz consuming taxa or isolates such as methanogenic archaea and homoacetogenic bacteria with 97% sequence similarity set as the species-level cut off (Konstantinidis, K. T. & Tiedje, J. M.
  • the 16S rRNA gene sequence V3-V4 hypervariable region was obtained for each sample by extraction from 16S reads obtained from capillary sequencing with the conserved forward (SEQ ID NO. p0001 : CCTACGGGNGGCWGCAG) and reverse (SEQ ID NO. p0002: GACTACHVGGGTATCTAATCC) regions as flanking markers using hyperex version 0.1.1 (Ebou, A., Koua, D. & Zeze, A. HyperEx: A Tool to Extract Hypervariable Regions from 16S rRNA Sequencing Data. bioRxiv 2021.09.03.455391 (2021 ) doi:10.1101/2021 .09.03.455391).
  • Resulting alignment files were input into FastTree V2.1.11 to infer maximum likelihood trees with the generalised time-reversible (GTR) with CAT approximation model. Trees were visualised with R package ggtree v3.6.2 and R package ggtreeExtra v1 .8.1 .
  • the inventors selected isolates for inclusion in the BB265 consortium that showed a negative phenotype for sulphide production. However, where this could not occur, rather than dismissing these sulphide producing isolates outright, the inventors considered their potential role in ulcerative colitis management due to their prevalence in healthy individuals, keystone characteristics and anti-correlation with ulcerative colitis datasets. This decision was driven due to the relationship between sulphide and ulcerative colitis being nuanced and multifaceted. While the inventors posit sulphide as the deleterious agent in the context of ulcerative colitis, the human gut microbiome is a diverse and complex ecosystem, and microbial diversity is crucial for health (Mosca, A., Leclerc, M.
  • sulphide production was identified as being a phylogenetically diverse phenotype, both present in taxa associated with health and ulcerative colitis. Isolates chosen for inclusion in the BB265 complex consortium were preferentially selected if they showed a negative phenotype for sulphide production; however, where this could not occur, isolates were still considered due to evidence for their association with health, importance as keystones, anticorrelation with ulcerative colitis, and hypothesised mechanisms of action, such as H2 consumption, which target sulphide production at the community level.
  • the amount of methylene blue produced is proportional to the original concentration of aqueous sulphide.
  • the presence of methylene blue can be determined spectrophotometrically via absorption of light at 667 nm
  • Negative controls consisting of modified YCFA (lacking L-cysteine) plus 2mM NaS without culture were prepared concurrently. Cuvettes were left to incubate anaerobically at 37 °C for 48 hr. Post incubation, growth of microbial isolates were identified visually by the presence of turbidity in cuvettes. Cuvettes were removed from the anaerobic cabinet, decapped and 200 pL culture broth added immediately to 3.8 mL dd.H 2 O in a clean cuvette.
  • Frozen isolates were thawed at 37 °C in the anaerobic cabinet, diluted 1 :10 in prereduced YCFA broth and left to incubate overnight. In triplicate, 100 pL overnight culture was used to inoculate 3.85 mL of modified YCFA broth (lacking L-cysteine) in a sterile cuvette spiked with 0.1 % L-serine.
  • Taxa that differed significantly from the negative control comprised species in the genera Alisipes, Anaerobutyricum, Anaerofustis, Bacteroides, Blautia, Christensenella, Clostrdium, Collinsella, Coprobacillus, Coprococcus, Erysipelatoclostridium, Eubacterium, Flavonifractor, Intestinimonas, Longicatena, Massilimicrobiota, Parabacteroides, Roseburia, Ruminococcus, Streptococcus, and Thomasclavelia.
  • Sulphide is a cytotoxic metabolite produced in excess by resident colonic microbiota in patients with inflammatory bowel disease.
  • Sulphide in this experiment is measured in the form of a sulphide ion (S 2 ‘); a hydrosulphide (HS j ion; a bisulphide ion (SH' ), and hydrogen sulphide (H2S).
  • Microbiota-derived sulphide in combination with nitric oxide plays a direct role in ulcerative colitis (UC) pathogenesis.
  • UC ulcerative colitis
  • These gases lead to sequestration of CoA, and depletion of glutathione and an inability of colonocytes (colonic epithelial cells) to produce energy via p-oxidation of butyrate.
  • This biochemical lesion in ulcerative colitis results in an energy-deprived state for colonocytes and contributes to a loss of epithelial barrier function and ensuing mucosal inflammation.
  • sulphide in faecal samples has been found to be 3-4 fold higher in ulcerative colitis than in control cases. This is likely due to the relatively high levels of sulfidogenic microbiota, including SRB and cysteine degrading bacteria in patients with inflammatory bowel disease in both active and quiescent disease. Nitric oxide is produced by both inflamed colonocytes and the colonic microbiota.
  • Faecal microbiota transplantation has demonstrated efficacy in the induction of remission of ulcerative colitis, indicating that the colonic microbiota are involved in disease pathogenesis and that modulation of the colonic microbiota can ameliorate disease.
  • modulation of the colonic microbiome in a way that reduces colonic levels of sulphide offers a promising therapeutic target.
  • the final list of isolates comprising the BB265 consortium consisted of 143 microbial isolates (Table 2).
  • the BB265 complex consortium list is presented using the following taxonomic classifications.
  • NB Due to the ephemeral nature of taxonomic names, taxon IDs are also provided for each isolate in the BB265 consortium, including also those isolates not in the BB265 consortium but identified with a sulphide consumption phenotype ( Figure 5). All past, present and future taxon names describing each species are to be covered here, including all homotypic, heterotypic, subjective, objective, nomenclatural and invalid synonyms, along with misapplied names.
  • Table 4 List of taxa by Species / 16S identification including 16S sequences for each species in the BB265 complex consortium or identified as sulphidogens
  • the BB265 complex consortium was prepared as a mixed inoculum to be used going forward for validation experiments. Two mixed consortium inocula were prepared: (1 ) containing a subset of 127 isolates present in the final BB265 complex consortium (Table 8); this subset was prepared as validation experiments were undertaken before the remaining 16 isolates had completed screening as per section C.
  • Example 3 - Defining organisms comprising the BB265 complex community live biotherapeutic product.
  • the BB265 complex consortium was amended to additionally comprise these remaining 16 isolates post screening as they were considered as therapeutic candidates, and (2) the total BB265 complex consortium comprising the 143 isolates specified in section C.
  • Example 3 - Defining organisms comprising the BB265 complex community live biotherapeutic product Table 5).
  • Isolates comprising the inocula were grown anaerobically at 37 °C overnight in a Whitley A55 HEPA Anaerobic Workstation (Don Whitley Scientific) (atmosphere: 10% H2, 10% CO2, 80% N2) by inoculating 2.94 mL modified-YCFA broth with 30 pL thawed glycerol stocks of purified isolates. For slow growers, inoculation occurred the day prior and were incubated for 48 hours. Culture broth were then diluted 1 :1 in a Costar 48-well microplate to a final volume of 500 pL; diluted cultures were then read on a Spectrostar Nano spectrophotometer to determine OD 600 nm values.
  • Cultures were then diluted individually with modified YCFA to achieve an OD 600 nm per isolate of 0.2. Equal volumes of diluted culture broth were then combined, diluted 1 :1 in 50% glycerol (final concentration 25%) and frozen at -80 °C. Total cell concentration of the mixed inocula were then determined by quantifying intact cell counts using a BactoBox® (SBT Instruments) as per manufacturer’s instructions. Using OD 600 nm as a proxy for cell number, and assuming each isolate present in the mixed inocula were present in equal abundance, cell concentration per isolate was determined by dividing the total cell number by the number of isolates in the inoculum.
  • glycerol stocks were prepared as above and intact cell concentration per isolate determined using a BactoBox® (SBT Instruments) as per manufacturer’s instructions.
  • BactoBox® SBT Instruments
  • slow growing isolates were combined with inocula at volumes adjusted to equalise cell concentration of all isolates in the inocula. These cell-number normalised mixes were then used as inocula for validation experiments moving forward.
  • Ulcerative colitis is a chronic inflammatory bowel disease derived from abnormal immune response, causing inflammation and ulceration of the colon and rectum.
  • Recent advancement in the study of human gut microbiota demonstrated the association between gut dysbiosis and the development and progression of ulcerative colitis symptoms.
  • One aspect of gut dysbiosis in ulcerative colitis patients is the imbalance of sulphide homeostasis, where excessive levels of sulphide can contribute to the pathogenesis of the disease.
  • Targeting sulphide production in the gut can be a potential therapeutic strategy for ulcerative colitis.
  • FMT faecal microbiota transplantation
  • This study aims to determine the correlation between the production of sulphide in vitro and the abundance levels of the BB265 complex consortium isolates in ulcerative colitis patients who received FMT intervention. The result informs a putative involvement of the FMT-derived BB265 complex consortium in sulphide reduction and disease remission in ulcerative colitis patients.
  • Phase 1 was a 12-week open label induction of ulcerative colitis remission
  • Phase 2 was a 40-week open label maintenance of remission study.
  • Phase 1 35 eligible patients received a tapering dose of oral prednisolone, starting with 50 mg daily weaning to 0 mg over 8 weeks.
  • Genomic DNA was extracted from patient faecal samples using the FastDNATM SPIN Kit for Soil DNA extraction kit (MPBio) as manufacturer's instructions. DNA quality was assessed using NanoDrop 2000c UV-vis spectrophotometer (Thermo Fisher, Waltham, MA, USA) and DNA subjected to metagenomic sequencing. DNA libraries were prepared using Celero EZTM DNA-Seq kits using protocol M01526 v1 and sequenced on an Illumina NextSeq2000 machine (109 bp PE), using Illumina protocol 1000000109376 v3. Metagenomes were quality trimmed and adapter sequences were removed with Trimmomatic v0.39, with leading and trailing bases below quality score 3 removed and reads below 50 base pairs removed.
  • MetaPhlAn4 v4.0.6
  • MetaPhlAn4 database v mpa_vOct22_CHOCOPhlAnSGB_202212.
  • MetaPhlAn4 outputs were merged and filtered for species-level results and the resulting data was used to identify taxonomic changes between samples of individuals who entered clinical and endoscopic remission, as defined above, and those who remained in active disease at the cessation of phase 1 .
  • the species MetaPhlAn4 output was filtered for baseline and remission samples for patient D (week 0 and week 52 samples) and E (week 0 and week 12 samples).
  • BB265 species names identified by BLAST comparison to the NCBI RefSeq 16S rRNA database, were queried by species name against the species taxa in the MetaPhlAn4 output. Through matching of taxa names, the number of matches, and the cumulative abundance of BB265 species in the metagenomes was calculated and compared between baseline and remission samples. This was repeated for species identified phenotypically as statistically significant consumers (Table 1 ).
  • a sulphide producing species list was generated by identifying species that had >70% of isolates in that species phenotypically identified as sulphide producers ( Figure 11 ). Any BB265 species were removed from the list of sulphide producer species, and the resulting list of species was queried against the MetaPhlAn output for patients D and E, and the number of species matches, and cumulative abundance of species were compared between the baseline and remission samples.
  • GC gas chromatography
  • Solution I is a minimal medium, providing low-dose complex carbon sources as the only nutrient source to kickstart fermentation whilst minimising medium complexity to maintain the metabolic milieu as present in uclerative colitis stool.
  • Solution I consists of the vitamin and mineral components of YCFA only with 5 g/L tryptone and 1 .25 g/L yeast extract.
  • GC vials were removed from the anaerobic chamber and 200 pL of the mixture was transferred to cuvettes containing 3.8 mL of RO water.
  • 345 pL of a solution containing FeCI3 (37.0 mM) and N, N-dimethyl-p-phenylenediamine sulphate salt (17.1 mM) dissolved in HCI (6 M) was added, the cuvette was immediately capped and inverted once to mix. Cuvettes were left for 10 min to allow for colour development and reaction to run to completion. 1 mL of the samples were transferred to Eppendorf tubes and centrifuged at 15,000 x g for 5 min.
  • Results [00451] Analysis of the metagenomes from phase 1 of the clinical trial dataset, identified that patients who went into remission (Clinical remission) had a significant increase in the number of BB265 species from week 0 to week 12. For patients who did not go into remission, the number of BB265 species did not change significantly between baseline and remission samples ( Figure 12a). Patients who did not enter clinical remission also had a significant decrease in sulphide consumer abundance from baseline to week 12 ( Figure 12b).
  • BB265 species are important gut microbiota in the induction of remission for ulcerative colitis.
  • the number of BB265 species and sulphide consumer species significantly increased from baseline to week 12 for patients that went into remission. Additionally, the statistically significant reduction in the relative abundance of consumer species in patients who did not enter remission also supports those isolates identified as sulphide consumers as a potential therapeutic for the treat ulcerative colitis.
  • the results of the modified methylene blue assay correlated directly with the clinical data, where a reduction of aqueous sulphide in vitro corresponded to a decrease in total Mayo score in clinical observation.
  • the total Mayo score reduced from 3 in week 0 to 0 in week 52 and the modified methylene blue assay testing showed a significant decrease in the levels of aqueous sulphide in the clinical sample from week 0 to week 52.
  • this correlation was also observed for Patient E, where the total Mayo score reduced from 8 in week 0 to 0 in week 12. This corresponded to elevated sulphide levels in the week 0 clinical sample and a significantly reduced level of hydrogen sulphide in the week 12 sample where the patient had achieved clinical remission.
  • the BB265 complex consortium consists of a diverse array of metabolically active bacteria found in the healthy human gut microbiome. These bacteria are likely to play pivotal roles within the sulphur pathways of the human gut, contributing in diverse ways such as metabolising sulphur substrates, redirecting sulphide into various metabolites, and effectively consuming sulphide.
  • a bacterial consortium comprising 127 of the 143 isolates in the BB265 complex consortium was grown overnight anaerobically at 37 °C by inoculating 50 L of cell-number normalised glycerol stock into 20 mL of YCFA (Table 8).
  • a phylogenetically diverse consumer mix (PDCM) (Table 9), consisting of 19 phylogenetically diverse isolates, each identified to consume sulphide (range 20-670 pM) whilst being confirmed negative for su phide production was run in parallel to the 127-isolate subset of the BB265 complex consortium.
  • the PDCM was run in parallel to assess community effects of sulphide consumption by a consumer community as a comparison to the 127-isolate subset of the BB265 complex consortium which itself contains many health-associated sulphidogens.
  • BB265 complex consortium were inoculated into 20 mL of pre-reduced YCFA tubes and incubated at 37°C for 24 hours anaerobically. After incubation, the cultures were pelletised by centrifugation at 12,000 x g for 10 min. The pellets were washed three times with 50 mL prereduced PBS to remove residual medium and resuspended in 20 mL pre-reduced Solution I.
  • Two ulcerative colitis stool samples were used in this study, referred to here as Patient A and Patient B.
  • 16% (w/v) faecal slurries were prepared by adding 8 g of stool in a Falcon tube which was topped up with 50 mL of Solution I. Samples were vortexed for 5 min and pulsed briefly up to 100 rpm to pelletise large particles. 2.5 mL of supernatant was transferred to Hungate tubes containing 2.5 mL of Solution I, resulting in a final concentration of 8% (w/v) faecal slurry.
  • DNA libraries were prepared using Celero EZTM DNA-Seq kits using protocol M01526 v1 , and sequenced on an Illumina NextSeq2000 machine (109 bp PE), using Illumina protocol 1000000109376 v3. Reads were processed using a custom pipeline developed inhouse, which uses Trimmomatic v0.39 to remove adapters and low-quality bases, Bowtie2 v2.5.1 to align reads to the Human genome for removal, and Metaphlan v4.0.6 to quantify the abundance of taxa present in each sample.
  • Hungate tubes were removed from the anaerobic chamber and 200 pL of the mixture was transferred to cuvettes containing 3.8 mL of RO water. To this cuvette, 345 pL of a solution containing FeCI3 (37.0 mM) and N, N-dimethyl-p-phenylenediamine sulphate salt (17.1 mM) dissolved in HCI (6 M) was added, the cuvette was immediately capped and inverted once to mix. Cuvettes were left for 10 min to allow for colour development and reaction to run to completion.
  • microbiota comprising the BB265 complex consortium have therapeutic potential in ulcerative colitis by modulating the dynamics of both sulphide production and consumption, resulting in a net reduction in sulphide levels when these taxa are present in the faecal samples of ulcerative colitis patients.
  • the glycerol stock of the BB265 complex consortium bioreactor harvest (20 mL) was topped up to 50 mL with sterile pre-reduced PBS and immediately centrifuged at 12000 x g for 6 min. Concurrently, overnight grown bb0214 consumer was centrifuged at 12000 x g for 10 min. After decanting the supernatant, both pellets were washed with sterile 50 mL PBS three times. Pellets of the BB265 complex consortium and bb0214 were resuspended in 10 mL and 20 mL of Solution I, respectively, by vortexing.
  • Two ulcerative colitis stool samples (Patient A and C) were used in this study.
  • Different concentrations of faecal slurry were prepared per donor to measure adequate sulphide; concentration was determined prior by assaying faecal slurries for sulphide production at various concentrations using the modified methylene blue assay.
  • 7 g of stool sample from Patient A and 5 g of stool sample from Patient C were dissolved in 70 mL and 100 mL of pre-reduced Solution I, respectively.
  • the modified methylene blue assay is a highly specific assay to detect total sulphides (H2S, HS and S 2 ) in the aqueous phase of our bioreactor.
  • This method allows endpoint data to be collected, when fermentation has run to completion and concentrations of sulphide between the aqueous phase and headspace have equilibrated.
  • It does not allow real-time monitoring of the production of H2S in the bioreactor.
  • This study aims to utilise commercial H 2 S microsensors to monitor the production of H 2 S in a closed bioreactor system in real-time whilst serving as a validation method for the results seen using the modified methylene blue assay.
  • the H 2 S sensor(s) were connected to a fx-6 pA UniAmp amplifier and the SensorTrace Suite software was opened. The sensors were allowed a window of 2 hours minimum for pre-polarisation at 0 mV. This window of time was shortened in future uses based on the stability of the mV reading after 20 min.
  • a solution of sterile, pure water and a standard pH buffer at pH 4 were purged with pure nitrogen gas for a minimum of 20 min to remove any oxygen dissolved in solution.
  • a 200 mM solution of sodium sulphide was prepared in deoxygenated water by adding the required weight of sodium sulphide to the solution and very gently swirling with the lid on to prevent any oxygenation of the solution.
  • the sensor was inserted into a sterile vial of pure water to remove any residual hydrogen sulphide.
  • the millivolt (mV) signals corresponding to the respective concentrations of calibration points were then integrated into the curve, and the software was configured to create a standard curve, thereby preparing it for subsequent measurements.
  • the temperature sensor was connected to the fx-6 pA UniAmp amplifier and the SensorTrace Suite software was opened.
  • the temperature sensor was placed in the known temperatures of 0°C, 22°C and 81 °C until the signal was stable. These temperatures were determined against a calibrated alcohol thermometer.
  • the millivolt (mV) signals to the respective temperatures of calibration points were then integrated into the curve, and the software was configured to create a standard curve, thereby preparing it for subsequent measurements
  • the H2S needle-type sensors and temperature sensor were connected to the amperometry and temperature channels of the Fx-6 UniAmp, respectively. Subsequently, the sensors were initiated by scanning through the SensorTrace Logger software. Then, all sensors were securely placed inside a 37°C incubator and left for a few min until a stable signal was observed. Bottles containing samples were pierced with the H2S needle-type sensors until sensor tips were immersed in the stool suspension and incubated at 37°C. The recording time interval was adjusted to 300 seconds, and recording commenced while these samples incubated at 37°C for 24 hours. Following the incubation period, the recording was stopped, and the data was saved as an .xls file.
  • the use of individual H 2 S consumers may not consistently facilitate H 2 S reduction in some ulcerative colitis patients, as their effectiveness appears to depend on the inter-variability between patient samples.
  • the BB265 complex consortium consistently demonstrates the same phenotypic response in both samples, underscoring its beneficial role in supporting H 2 S reduction within the context of ulcerative colitis stool.
  • These results highlight the pivotal role played by the BB265 complex consortium in the scope of ulcerative colitis treatment.
  • the BB265 consortium exhibits the capacity to substantially mitigate the rate of H 2 S production, a factor of paramount importance within the colon environment of ulcerative colitis patients. This reduction total and rate of H 2 S holds significant therapeutic promise by effectively limiting the concentration of H 2 S generated at any given moment, potentially offering substantial benefits to individuals affected with ulcerative colitis and also IBD.
  • NO nitric oxide
  • mammalian cells such as colonocytes
  • intraluminal NO has been observed to be increased, working alongside sulphide to inhibit P-oxidation to starve the colonocyte of cellular energy ( Figure 1 ).
  • NO 2 ‘ Direct measurements of NO in stool are challenging due to its high reactivity and short half-life. As a result, measurements of NO 2 ‘ are frequently used as a surrogate marker for NO.
  • Nitrite is an intermediate product in the NO 3 "-NO 2 '-NO pathway, which is a common route for NO production in the gut.
  • NO 3 ⁇ is a stable and abundant molecule in the human diet, and it can be reduced to nitrite by certain commensal bacteria present in the gut. Subsequently, NO 2 " can be further converted to NO under specific conditions, such as low oxygen levels, acidic pH, or in the presence of microbial enzymes like nitrite reductases.
  • NO 2 ⁇ and NO exist in a dynamic equilibrium, with the conversion between the two influenced by environmental factors and enzymatic activities.
  • higher levels of NO 2 " in stool may indicate an increased potential for NO generation, further supporting the utility of nitrite measurement as a proxy for NO levels.
  • Patient samples were selected based on a positive sulphide phenotype observed in previous bioreactor experiments.
  • Patient C was chosen due to the observation that sulphide concentration in the stool sample was reduced when incubated with BB265 complex consortium and an individual sulphide consumer.
  • Patient D and E were selected as they showed clinical response and remission to FMT, and a significant reduction of sulphide concentrations in remission samples compared to baseline (active) samples.
  • GC vials containing 5% faecal slurry of Patient C were spiked with 100 pL washed BB265 complex consortium and bb0214. Control samples were spiked with 100pL of Solution I only. Samples of Patient D and E were left unspiked to compare the difference in NO Z ⁇ produced by the autochthonous mic’obial communities in baseline and remission samples.. Once inoculated, the GC vials were capped immediately and incubated anaerobically at 37 °C overnight. The experiment for Patient C was performed in triplicate whilst the experiment for Patient D and E was performed in duplicate due to limited sample weight.
  • a nitrite reduction test was performed using Microtest Nitrite 50 kit (Aquaspex). Post incubation, GC vials were removed from the anaerobic chamber and faecal slurries transferred from GC vials into Falcon tubes and centrifuged at 12,000 x g for 10 min. Then 1 mL of faecal slurry supernatant was transferred into a new Falcon tube containing 4 mL of RO water. To this Falcon tube, 5 drops of sulphuric acid were added, followed by 2 drops of indicator solution. The mixture was mixed by swirling each time 1 reagent was added.
  • titration solution was added 5 pL at a time, swirled to mix until the colour of the mixture changed from red to pale blue.
  • concentration of nitrite in the stool samples was calculated as follows:
  • Nitrite concentration (mg/L) [(Volume of Titration Stock Solution x 50 mg/L)/25 pL] x 5
  • Table 10 shows the concentrations of nitrite in the stool samples of Patient C, D and E after overnight incubation, with and without addition of the BB265 complex consortium and bb0214 consumer.
  • a reduction of nitrite was observed in Patient C from 450 mg/L (+ 50 SD) to 366.67 mg/L (+ 28.87 SD) after incubation with the BB265 complex consortium. No reduction was observed for samples incubated with bb0214.
  • the inventors' findings highlight the therapeutic potential of the BB265 complex consortium for the treatment of ulcerative colitis by modulating colonic sulphide and NO.
  • the parallel trends observed in the clinical FMT data and the BB265 complex consortium experiments provide compelling evidence for the validation of this mechanism of action specific to ulcerative colitis and also IBD.
  • the overnight grown 127-isolate subset of the BB265 complex consortium was centrifuged at 12000 x g for 10 min. After decanting the supernatant, pellets were washed with sterile 50 mL PBS three times. Final pellets were resuspended in 20 mL of sterile Solution I and vortexed to homogenise.
  • the 127-isolate subset of the BB265 complex consortium (100 pL) was inoculated as samples into stool suspensions with and without fibres. Additionally, 100 pL of sterile medium was inoculated into tubes containing stool samples only, serving as controls. Subsequently, the tubes were incubated anaerobically at 37 °C for 24 hours, and an endpoint measurement of sulphide content was performed using the modified methylene blue assay, following the methodology employed in previous experiments.
  • FOS, inulin, maltodextrin, and starch reduced sulphide levels in all three stool samples ranging from 111.8 pM to 223.6 pM, 147.7 pM to 230.8 pM, 104.6 pM to 198.0 pM, and 143.6 pM to 213.9 pM, respectively.
  • sulphide levels were altered to the ranges of 121.0 pM to 229.3 pM, 148.7 pM to 236.9 pM, 94.4 pM to 219.0 pM, and 142.6 pM to 213.9 pM, respectively (Figure 22).
  • the 127-isolate subset of the BB265 complex consortium when supplemented with inulin, exhibited the ability to efficiently reduce high levels of sulphide in stool samples from all patients.
  • This observation strongly suggests that the co-culture is proficient at promoting fibre fermentation over protein fermentation, particularly in the presence of inulin.
  • starch demonstrated lower sulphide consumption when combined with the 127-isolate subset, indicating its potentially limited fermentability by this consortium.
  • FOS and maltodextrin exhibited varying interactions with the 127- isolate subset of BB265, resulting in fluctuations in the concentrations of reduced sulphide, depending on stool variations. This underscores the notion that dietary fibres have an evident impact on the complex consortium in terms of sulphide reduction in patients with ulcerative colitis and provides evidence for including fibre with the BB265 therapy to potentiate its ability to reduce sulphide levels.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pour le traitement d'une maladie inflammatoire de l'intestin. La présente invention concerne également des formes pharmaceutiques et des méthodes de traitement d'une maladie inflammatoire de l'intestin par l'administration de la composition à un patient en ayant besoin.
PCT/GB2023/000044 2022-09-20 2023-09-20 Compositions et méthodes de réduction du sulfure endogène chez des patients atteints de maladies inflammatoires de l'intestin Ceased WO2024062208A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2025511325A JP2025531029A (ja) 2022-09-20 2023-09-20 炎症性腸疾患における内因性硫化物を低減させるための組成物および方法
CN202380067361.5A CN120435301A (zh) 2022-09-20 2023-09-20 用于减少炎症性肠病中内源性硫化物的组合物和方法
CA3264675A CA3264675A1 (fr) 2022-09-20 2023-09-20 Compositions et méthodes de réduction du sulfure endogène chez des patients atteints de maladies inflammatoires de l'intestin
IL319782A IL319782A (en) 2022-09-20 2023-09-20 Compositions and methods for reducing endogenous sulfide in inflammatory bowel diseases
AU2023345834A AU2023345834A1 (en) 2022-09-20 2023-09-20 Compositions and methods for reducing endogenous sulphide in inflammatory bowel diseases
EP23783935.2A EP4577226A1 (fr) 2022-09-20 2023-09-20 Compositions et méthodes de réduction du sulfure endogène chez des patients atteints de maladies inflammatoires de l'intestin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2022902716A AU2022902716A0 (en) 2022-09-20 Compositions and Methods for Reducing Endogenous Sulphide in Inflammatory Bowel Diseases
AU2022902716 2022-09-20

Publications (1)

Publication Number Publication Date
WO2024062208A1 true WO2024062208A1 (fr) 2024-03-28

Family

ID=88287440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2023/000044 Ceased WO2024062208A1 (fr) 2022-09-20 2023-09-20 Compositions et méthodes de réduction du sulfure endogène chez des patients atteints de maladies inflammatoires de l'intestin

Country Status (7)

Country Link
EP (1) EP4577226A1 (fr)
JP (1) JP2025531029A (fr)
CN (1) CN120435301A (fr)
AU (1) AU2023345834A1 (fr)
CA (1) CA3264675A1 (fr)
IL (1) IL319782A (fr)
WO (1) WO2024062208A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024187244A1 (fr) * 2023-03-15 2024-09-19 Cost-Bry Pty Ltd (trading as BiomeBank) Compositions de microbiote et méthodes de traitement de troubles
WO2025035190A1 (fr) * 2023-08-16 2025-02-20 Cost-Bry Pty Ltd (trading as BiomeBank) Nouveaux consortiums microbiens co-cultivés

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338671A (en) 1992-10-07 1994-08-16 Eastman Kodak Company DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody
US5710029A (en) 1995-06-07 1998-01-20 Gen-Probe Incorporated Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US6150097A (en) 1996-04-12 2000-11-21 The Public Health Research Institute Of The City Of New York, Inc. Nucleic acid detection probes having non-FRET fluorescence quenching and kits and assays including such probes
US6174670B1 (en) 1996-06-04 2001-01-16 University Of Utah Research Foundation Monitoring amplification of DNA during PCR
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
US6534274B2 (en) 1998-07-02 2003-03-18 Gen-Probe Incorporated Molecular torches
US6541205B1 (en) 1999-05-24 2003-04-01 Tosoh Corporation Method for assaying nucleic acid
WO2006102536A2 (fr) * 2005-03-23 2006-09-28 University Of Southern California Traitement d'etats pathologiques par modulation du sulfure d'hydrogene produit par la proliferation bacterienne de l'intestin grele
WO2017148596A1 (fr) * 2016-03-04 2017-09-08 4D Pharma Plc Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
WO2019075344A1 (fr) * 2017-10-12 2019-04-18 Crestovo Holdings Llc Transplantation de microbiote fécal pour traiter la rectocolite hémorragique
US20200323927A1 (en) * 2016-03-04 2020-10-15 4D Pharma Plc Compositions comprising bacterial strains
WO2021016081A1 (fr) * 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Méthodes et produits destinés au traitement de troubles gastro-intestinaux
WO2021016083A1 (fr) * 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc Methodes et produits pour le traitement de troubles gastro-intestinaux

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587287A (en) 1992-10-07 1996-12-24 Johnson & Johnson Clinical Diagnostics, Inc. Thermostable polymerase specific antibody-containing DNA amplification composition and kit
US5338671A (en) 1992-10-07 1994-08-16 Eastman Kodak Company DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5710029A (en) 1995-06-07 1998-01-20 Gen-Probe Incorporated Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
US6150097A (en) 1996-04-12 2000-11-21 The Public Health Research Institute Of The City Of New York, Inc. Nucleic acid detection probes having non-FRET fluorescence quenching and kits and assays including such probes
US6174670B1 (en) 1996-06-04 2001-01-16 University Of Utah Research Foundation Monitoring amplification of DNA during PCR
US6534274B2 (en) 1998-07-02 2003-03-18 Gen-Probe Incorporated Molecular torches
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
US6541205B1 (en) 1999-05-24 2003-04-01 Tosoh Corporation Method for assaying nucleic acid
WO2006102536A2 (fr) * 2005-03-23 2006-09-28 University Of Southern California Traitement d'etats pathologiques par modulation du sulfure d'hydrogene produit par la proliferation bacterienne de l'intestin grele
WO2017148596A1 (fr) * 2016-03-04 2017-09-08 4D Pharma Plc Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
US20200323927A1 (en) * 2016-03-04 2020-10-15 4D Pharma Plc Compositions comprising bacterial strains
WO2019075344A1 (fr) * 2017-10-12 2019-04-18 Crestovo Holdings Llc Transplantation de microbiote fécal pour traiter la rectocolite hémorragique
WO2021016081A1 (fr) * 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Méthodes et produits destinés au traitement de troubles gastro-intestinaux
WO2021016083A1 (fr) * 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc Methodes et produits pour le traitement de troubles gastro-intestinaux

Non-Patent Citations (35)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING CO.
"Standard Methods For the Examination of Water and Wastewater", 2017, PUBLIC HEALTH ASSOCIATION
"Sustained and Controlled Release Drug Delivery Systems", 1978, MARCEL DEKKER, INC.
BANERJEE, S.SCHLAEPPI, K.VAN DER HEIJDEN, M. G. A.: "Keystone taxa as drivers of microbiome structure and functioning", NAT. REV. M CROBIO!, vol. 16, 2018, pages 567 - 576, XP036653799, DOI: 10.1038/s41579-018-0024-1
BANERJEE, S.SCHLAEPPI, K.VAN DER HEIJDEN, M. G. A.: "Keystone taxa as drivers of microbiome structure and functioning", NAT. REV. MICROBIOL., vol. 16, 2018, pages 567 - 576, XP036653799, DOI: 10.1038/s41579-018-0024-1
BEATTY, E. R.CUMMINGS, J. H: "The contribution of sulphate- reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis", GUT, vol. 46, 2000, pages 64 - 72, XP055303938, DOI: 10.1136/gut.46.1.64
CHNG, K. R. ET AL.: "Metagenome-wide association analysis identifies microbial determinants of post-antibiotic ecological recovery in the gut.", NATURE ECOLOGY & EVOLUTION, vol. 4, 2020, pages 1256 - 1267, XP037231338, DOI: 10.1038/s41559-020-1236-0
COSTELLO S. P. ET AL: "Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol. 46, no. 3, 1 August 2017 (2017-08-01), GB, pages 213 - 224, XP055873968, ISSN: 0269-2813, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fapt.14173> DOI: 10.1111/apt.14173 *
EBOU, A.KOUA, D.ZEZE, A.: "HyperEx: A Tool to Extract Hypervariable Regions from 16S rRNA Sequencing Data", BIORXIV, 3 September 2021 (2021-09-03), pages 455391
GIBSON, G. R.CUMMINGS, J. H.MACFARLANE, G. T.: "Growth and activities of sulphate-reducing bacteria in gut contents of healthy subjects and patients with ulcerative colitis", FEMS MICROBIOL. LETT., vol. 86, 1991, pages 103 - 111, XP023922422, DOI: 10.1111/j.1574-6968.1991.tb04799.x
GLOOR, G.: "ALDEx2: ANOVA-Like Differential Expression tool for compositional data", ALDEX MANUAL MODULAR, vol. 20, 2015, pages 1 - 11
HAJISHENGALLIS, G.DARVEAU, R. P.CURTIS, M. A: "The keystone-pathogen hypothesis", NAT. REV. MICROBIOL., vol. 10, 2012, pages 717 - 725
JENNIE C. HUNTER-CEVERA: "Maintaining Cultures for Biotechnology and Industry", 1996, ACADEMIC PRESS
KONSTANTINIDIS, K. T.TIEDJE, J. M: "Genomic insights that advance the species definition for prokaryotes.", PROC. NATL. ACAD. SCI. U. S. A., vol. 102, 2005, pages 2567 - 2572, XP055692951, DOI: 10.1073/pnas.0409727102
LIN, H.PEDDADA, S. D.: "Analysis of compositions of microbiomes with bias correction.", NAT. COMMUN., vol. 11, 2020, pages 3514
LU, J.BREITWIESER, F. P.THIELEN, P.SALZBERG, S. L.: "Bracken: estimating species abundance in metagenomics data", PEERJ COMPUT. SCI., vol. 3, 2017, pages e104
M C L PITCHER ET AL: "The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis", GUT MICROBIOTA, vol. 46, no. 1, 1 January 2000 (2000-01-01), UK, pages 64 - 72, XP055303938, ISSN: 0017-5749, DOI: 10.1136/gut.46.1.64 *
MOSCA, A., LECLERC, M. & HUGOT, J. P.: "Gut Microbiota Diversity and Human Diseases: Should We Reintroduce Key Predators in Our Ecosystem?", FRONT. MICROBIOL., vol. 7, 2016, pages 455
PLUGGE, C. M.ZHANG, W.SCHOLTEN, J. C. M.STAMS, A. J. M.: "Metabolic flexibility of sulfate-reducing bacteria", FRONT. MICROBIOL., vol. 2, 2011, pages 81
RIVERA-PINTO, J.: "Balances: a new perspective for microbiome analysis", MSYSTEMS, 2018
ROEDIGER W E W ET AL: "COLONIC SULFIDE IN PATHOGENESIS AND TREATMENT OF ULCERATIVE COLITIS", DIGESTIVE DISEASES AND SCIENCES, SPRINGER NEW YORK LLC, US, vol. 42, no. 8, 1 August 1997 (1997-08-01), pages 1571 - 1579, XP000973143, ISSN: 0163-2116, DOI: 10.1023/A:1018851723920 *
ROEDIGER, W.BABIDGE, W.: "Nitric oxide effect on coloncyte metabolism: Co-action of sulphides and peroxide", AN INTERNATIONAL JOURNAL FOR CHEMICAL BIOLOGY IN HEALTH AND DISEASE, vol. 206, 2000, pages 159 - 167
RONALD ATLAS: "Handbook of Microbiological Media", 2010, CRC PRESS
ROTTJERS, L.FAUST, K.: "Can we predict keystones?", NATURE REVIEWS. MICROBIOLOGY, vol. 17, 2019, pages 193
SEEMANN, T.: "Prokka: rapid prokaryotic genome annotation", BIOINFORMATICS, vol. 30, 2014, pages 2068 - 2069, XP093034914, DOI: 10.1093/bioinformatics/btu153
SHARON, I. ET AL.: "The Core Human Microbiome: Does It Exist and How Can We Find It? A Critical Review of the Concept", NUTRIENTS, 2022, pages 14
TEIGEN, L. M. ET AL.: "Dietary Factors in Sulfur Metabolism and Pathogenesis of Ulcerative Colitis", NUTRIENTS, 2019, pages 11
THOMPSON ET AL., NUCLEIC ACIDS RESEARCH, vol. 22, 1994, pages 4673 - 4680
TSAI, H. H.SUNDERLAND, D.GIBSON, G. R.HART, C. A.RHODES, J. M. A: "novel mucin sulphatase from human faeces: its identification, purification and characterization", CLIN. SCI., vol. 82, 1992, pages 447 - 454
WELCH, B. L.: "The Generalization of'Student's' Problem when Several Different Population Variances are Involved", BIOMETRIKA, vol. 34, 1947, pages 28 - 35
WOLF, P. G. ET AL.: "Diversity and distribution of sulphur metabolism in the human gut microbiome and its association with colorectal cancer", BIORXIV, 1 July 2021 (2021-07-01), pages 450790
WOOD, D. E.LU, J.LANGMEAD, B.: "Improved metagenomic analysis with Kraken 2", GENOME BIOL., vol. 20, 2019, pages 257
YAO C K ET AL: "Review article: insights into colonic protein fermentation, its modulation and potential health implications", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, BLACKWELL SCIENTIFIC PUBLICATIONS LTD., CAMBRIDGE, GB, vol. 43, no. 2, 2 November 2015 (2015-11-02), pages 181 - 196, XP071544010, ISSN: 0269-2813, DOI: 10.1111/APT.13456 *
YAO, C. K. ET AL.: "Modulation of colonic hydrogen sulphide production by diet and mesalazine utilizing a novel gas-profiling technology", GUT MICROBES, vol. 9, 2018, pages 510 - 522, XP055734642, DOI: 10.1080/19490976.2018.1451280
ZE, X.DUNCAN, S. H.LOUIS, P.FLINT, H. J.: "Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon", ISME J., vol. 6, 2012, pages 1535 - 1543

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024187244A1 (fr) * 2023-03-15 2024-09-19 Cost-Bry Pty Ltd (trading as BiomeBank) Compositions de microbiote et méthodes de traitement de troubles
WO2025035190A1 (fr) * 2023-08-16 2025-02-20 Cost-Bry Pty Ltd (trading as BiomeBank) Nouveaux consortiums microbiens co-cultivés

Also Published As

Publication number Publication date
CN120435301A (zh) 2025-08-05
AU2023345834A1 (en) 2025-03-06
IL319782A (en) 2025-05-01
EP4577226A1 (fr) 2025-07-02
CA3264675A1 (fr) 2024-03-28
JP2025531029A (ja) 2025-09-19

Similar Documents

Publication Publication Date Title
US11918612B2 (en) Synergistic bacterial compositions and methods of production and use thereof
US10881696B2 (en) Network-based microbial compositions and methods
ES2960053T3 (es) Tratamiento de infección por Clostridium difficile
Mättö et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome—a longitudinal study in IBS and control subjects
Leclerc et al. Nitric oxide impacts human gut microbiota diversity and functionalities
EP4233884A2 (fr) Compositions bactériennes conçues
WO2007136553A2 (fr) Souches bactériennes, compositions les contenant et utilisation probiotique de ces souches
JP2016519664A5 (fr)
US20210269860A1 (en) Person-specific assessment of probiotics responsiveness
Hecht et al. Dietary carbohydrates regulate intestinal colonization and dissemination of Klebsiella pneumoniae
EP4577226A1 (fr) Compositions et méthodes de réduction du sulfure endogène chez des patients atteints de maladies inflammatoires de l&#39;intestin
US20250305068A1 (en) New biomarker for disorders and diseases associated with intestinal dysbiosis
Deschamps et al. Development of a new antibiotic-induced dysbiosis model of the canine colonic microbiota
WO2025035190A1 (fr) Nouveaux consortiums microbiens co-cultivés
WO2021173895A1 (fr) Analyse du microbiome pour le diagnostic et le traitement de maladie des calculs urinaires
Strain et al. A pilot study of dietary fibres on pathogen growth in an ex vivo colonic model reveals their potential ability to limit vancomycin-resistant Enterococcus expansion
Mengoli Drug and probiotics-based intervention strategies for the restoration of gut microbiome dysbiosis
US20250228905A1 (en) Microbial communities that inhibit clostridioides difficile and methods of using same
Wolf Microbial pathways of sulfur metabolism and colorectal cancer risk
Fehlbaum et al. Design and investigation of PolyFermS
Ene Exploring the Role of Lactobacillus jensenii and Lactobacillus mulieris in the Urogenital Tract
Zhu et al. The substrate-binding protein DppA modulates the virulence of hypervirulent Klebsiella pneumoniae
Wetthasinghe et al. Effect of exclusive enteral nutrition on gut microbiota in Malaysian children with Crohn’s disease
Langdon Gut Reactions: Quantitative Predictions of the Responses of Human Gut Microbiota to Medical Interventions
Fradejas et al. Campylobacter jejuni pericarditis in a renal transplant recipient on sirolimus therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23783935

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2023345834

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2025511325

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025511325

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2023345834

Country of ref document: AU

Date of ref document: 20230920

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 319782

Country of ref document: IL

Ref document number: 202380067361.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2023783935

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2023783935

Country of ref document: EP

Effective date: 20250327

WWE Wipo information: entry into national phase

Ref document number: 202547037838

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 202547037838

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2023783935

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 202380067361.5

Country of ref document: CN